Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/695—Silicon compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • C07D498/16—Peri-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/0803—Compounds with Si-C or Si-Si linkages
  • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
  • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/0803—Compounds with Si-C or Si-Si linkages
  • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
  • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
  • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• KRAS G12D MODULATING COMPOUNDS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. provisional application no.63/333,347, filed April 21, 2022, U.S. provisional application no. 63/353,726, filed June 20, 2022, and U.S. provisional application no. 63/386,651, filed December 8, 2022, which are incorporated herein in their entireties for all purposes.
• the KRAS protein Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (“KRAS”), is a GTPase.
• KRAS gene mutations have been observed in a number of conditions including, for instance, pancreatic cancer, endometrial cancer, lung adenocarcinoma, colorectal cancer, rectal carcinoma, gall bladder cancer, thyroid cancer, bile duct cancer, small cell lung cancer, and non- small cell lung cancer (NSCLC). Accordingly, there is a need for compounds, pharmaceutical compositions, and methods for inhibiting KRAS (e.g., KRAS G12C and/or KRAS G12D) and treating associated cancers.
• KRAS e.g., KRAS G12C and/or KRAS G12D
• the present disclosure provides a compound of Formula I: Formula I, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; R 1 , R 2 , R 3 , and R 4 are each independently H or C 1 -C 3 alkyl; L 1 is O, S, or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl
• the present disclosure provides a compound of Formula I-A: Formula I-A, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; L 1 is O, S, or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl; L 2 is CR 2a R 2b ; alternatively, L 2 is O or S, and L 1 is CR 1
• the present disclosure provides a compound of Formula II: Formula II, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; L 1 is O or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl; L 2 is CR 2a R 2b ; R 2a and R 2b are each independently H, C 1 -C 3 alkyl, C 1
• the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, and a pharmaceutically acceptable excipient.
• the present disclosure provides a method of inhibiting KRAS G12D protein in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
• the present disclosure provides a method for manufacturing a medicament for treating cancer in a subject in need thereof, characterized in that a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is used.
• the present disclosure provides a method for manufacturing a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of the present invention, or a pharmaceutically acceptable salt thereof, is used.
• the present disclosure provides use of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer in a subject.
• the present disclosure provides use of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting cancer metastasis in a subject.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject in need thereof.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in inhibiting cancer metastasis in a subject in need thereof.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in therapy.
• the disclosure relates generally to methods
• a dash at the front or end of a chemical group is a matter of convenience; chemical groups can be depicted with or without one or more dashes without losing their ordinary meaning.
• a wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
• a compound of the disclosure can mean a compound of any of the Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib- 7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), and (IIb-2), or a pharmaceutically acceptable salt thereof.
• the phrase “a compound of Formula (number)” means a compound of that formula and pharmaceutically acceptable salts thereof.
• C u -C v indicates that the following group has from u to v carbon atoms.
• C 1- C 8 alkyl indicates that the alkyl group has from 1 to 8 carbon atoms.
• Alkyl refers to an unbranched or branched saturated hydrocarbon chain.
• an alkyl group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 alkyl), 1 to 8 carbon atoms (i.e., C 1 -C 8 alkyl), 1 to 6 carbon atoms (i.e., C 1 -C 6 alkyl), or 1 to 3 carbon atoms (i.e., C 1 -C 3 alkyl).
• alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1-propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1-butyl (n-Bu, n- butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl (i-Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s- butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n- pentyl, -CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )
• alkyl groups include, but are not limited to, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, pentadcyl, hexadecyl, heptadecyl and octadecyl.
• Alkenyl refers to an unbranched or branched hydrocarbon chain containing at least two carbon atoms and at least one carbon-carbon double bond.
• alkenyl can have from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkenyl).
• Alkenyl can include any number of carbons, such as C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , or any range therein.
• Alkenyl groups can have any suitable number of double bonds, including, but not limited to, 1, 2, 3, 4, 5 or more.
• alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl.
• Alkynyl refers to an unbranched or branched hydrocarbon chain containing at least one carbon-carbon triple bond.
• an alkynyl group can have from 2 to 20 carbon atoms (i.e., C 2-20 alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C 2-4 alkynyl).
• alkynyl also includes those groups having one triple bond and one double bond.
• C 2-6 alkynyl examples include, but are not limited to, ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-4-ynyl and penta-1,4-diynyl.
• Alkoxy means a group having the formula –O-alkyl, in which an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom.
• the alkyl portion of an alkoxy group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 alkoxy), 1 to 12 carbon atoms (i.e., C 1 -C 12 alkoxy), 1 to 8 carbon atoms (i.e., C 1 -C 8 alkoxy), 1 to 6 carbon atoms (i.e., C 1 -C 6 alkoxy) or 1 to 3 carbon atoms (i.e., C 1 -C 3 alkoxy).
• alkoxy groups include, but are not limited to, methoxy (-O-CH 3 or –OMe), ethoxy (-OCH 2 CH 3 or -OEt), isopropoxy (-O-CH(CH 3 ) 2 ), t-butoxy (-O-C(CH 3 ) 3 or –OtBu) and the like.
• suitable alkoxy groups include, but are not limited to, sec-butoxy, tert-butoxy, pentoxy, hexoxy, and the like.
• Alkoxyalkyl refers an alkoxy group linked to an alkyl group which is linked to the remainder of the compound.
• Alkoxyalkyl can have any suitable number of carbon, such as from 2 to 6 (C 2-6 alkoxyalkyl), 2 to 5 (C 2-5 alkoxyalkyl), 2 to 4 (C 2-4 alkoxyalkyl), or 2 to 3 (C 2-3 alkoxyalkyl).
• Alkoxy and alkyl are as defined above. Examples of “alkoxyalkyl” include, but are not limited to, methoxymethyl (CH 3 OCH 2 -), and methoxyethyl (CH 3 OCH 2 CH 2 ).
• “Bridged” means a ring system in which non-adjacent atoms on a ring are connected by a divalent substituent, such as an alkylenyl or heteroalkylenyl group or a single heteroatom.
• “Hydroxyalkyl” refers to a hydroxy group, -OH, linked to an alkyl group which is linked to the remainder of the compound such that the alkyl group is divalent.
• Hydroxyalkyl can have any suitable number of carbons, such as from 1 to 8 (C 1-8 hydroxyalkyl), 1 to 6 (C 1- 6 hydroxyalkyl), 2 to 6 (C 2-6 hydroxyalkyl), 2 to 4 ( C 2-4 hydroxyalkyl), or 2 to 3 (C 2 - 3 hydroxyalkyl).
• Alkyl is as defined above where the alkyl is divalent.
• Halo or “halogen” as used herein refers to fluoro (-F), chloro (-Cl), bromo (-Br) and iodo (-I).
• Haloalkyl is an alkyl group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
• the alkyl portion of a haloalkyl group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 haloalkyl), 1 to 12 carbon atoms (i.e., C 1 -C 12 haloalkyl), 1 to 8 carbon atoms (i.e., C 1 -C 8 haloalkyl), 1 to 6 carbon atoms (i.e., C 1 -C 6 alkyl) or 1 to 3 carbon atoms (i.e., C 1 -C 3 alkyl).
• the alkyl groups can be substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more halogens.
• suitable haloalkyl groups include, but are not limited to, -CF 3 , -CHF 2 , -CFH 2 , -CH 2 CF 3 , fluorochloromethyl, difluorochloromethyl, 1,1,1-trifluoroethyl and pentafluoroethyl.
• Haloalkoxy refers to an alkoxy group where some or all of the hydrogen atoms are substituted with halogen atoms.
• haloalkoxy groups can have any suitable number of carbon atoms, such as C 1-6 .
• the alkoxy groups can be substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more halogens. When all the hydrogens are replaced with a halogen, for example by fluorine, the compounds are per-substituted, for example, perfluorinated.
• Haloalkoxy includes, but is not limited to, trifluoromethoxy, 2,2,2,-trifluoroethoxy, perfluoroethoxy, etc.
• Thioalkyl refers to a thio group, -SH, linked to an alkyl group which is linked to the remainder of the compound such that the alkyl group is divalent.
• Thioalkyl can have any suitable number of carbons, such as from 1 to 8 (C 1-8 thioalkyl), 1 to 6 (C 1-6 thioalkyl), 2 to 6 (C 2- 6 thioalkyl), 2 to 4 (C 2-4 thioalkyl), or 2 to 3 (C 2-3 thioalkyl).
• Alkyl is as defined above where the alkyl is divalent.
• “Haloalkylthio” is an alkylthio group, as defined above, in which one or more hydrogen atoms of the alkyl group is replaced with a halogen atom.
• the alkyl portion of a haloalkylthio group can have 1 to 20 carbon atoms (i.e., C 1 -C 20 haloalkylthio), 1 to 12 carbon atoms (i.e., C 1 - C 12 haloalkylthio), 1 to 8 carbon atoms (i.e., C 1 -C 8 haloalkylthio), 1 to 6 carbon atoms (i.e., C 1 -C 6 alkylthio) or 1 to 3 carbon atoms (i.e., C 1 -C 3 alkylthio).
• the alkylthio groups can be substituted with 1, 2, 3, 4, 5, 6, 7, 8, 9 or more halogens.
• Heteroalkyl refers to an unbranched or branched saturated hydrocarbon chain containing from 1 to 4 heteroatoms.
• Cyanoalkyl refers to a cyano group, -CN, linked to an alkyl group which is linked to the remainder of the compound such that the alkyl group is divalent. Cyanoalkyl can have any suitable number of carbons, such as from 1 to 8 (C 1-8 cyanoalkyl), 1 to 6 (C 1-6 cyanoalkyl), 2 to 6 (C 2 - 6 cyanoalkyl), 2 to 4 (C 2-4 cyanoalkyl), or 2 to 3 (C 2-3 cyanoalkyl).
• Alkyl is as defined above where the alkyl is divalent.
• “Cycloalkyl” refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings, such as 2, 3, 4 or more, wherein the multiple rings can be fused, bridged, spiro, or any combination thereof.
• cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl).
• cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups also include partially unsaturated ring systems containing one or more double bonds, including fused ring systems with one aromatic ring and one non-aromatic ring, but not fully aromatic ring systems. [0038] The term “fused” refers to a ring system in which two or more rings in the system share a pair of adjacent ring atoms. [0039] “Spiro” refers to at least two rings are linked together by one common atom.
• “Spiro” also refers to a ring substituent which is joined by two bonds at the same carbon atom.
• examples of spiro groups include, but are not limited to, 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4- benzyl-4-methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
• Alkyl-cycloalkyl refers to a radical having an alkyl component and a cycloalkyl component, where the alkyl component links the cycloalkyl component to the point of attachment.
• the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the cycloalkyl component and to the point of attachment. In some instances, the alkyl component can be absent.
• the alkyl component can include any number of carbons, such as C 1-6 , C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
• the cycloalkyl component is as defined within.
• alkyl-cycloalkyl groups include, but are not limited to, methyl-cyclopropyl, methyl-cyclobutyl, methyl-cyclopentyl and methyl-cyclohexyl.
• “Heterocycle” or “heterocyclyl” or “heterocycloalkyl” refer to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen, sulfur and silicon.
• a heterocyclyl can be a single ring or multiple rings, such as 2, 3, 4 or more, wherein the multiple rings can be fused, bridged, spiro, or any combination thereof.
• heterocyclyl has 3 to 20 ring atoms (i.e., 3 to 20 membered heterocyclyl), 3 to 12 ring atoms (i.e., 3 to 12 membered heterocyclyl), 3 to 10 ring atoms (i.e., 3 to 10 membered heterocyclyl), 3 to 8 ring atoms (i.e., 3 to 8 membered heterocyclyl), 4 to 12 ring carbon atoms (i.e., 4 to 12 membered heterocyclyl), 4 to 8 ring atoms (i.e., 4 to 8 membered heterocyclyl), or 4 to 6 ring atoms (i.e., 4 to 6 membered heterocyclyl).
• heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
• Alkyl-heterocycloalkyl refers to a radical having an alkyl component and a heterocycloalkyl component, where the alkyl component links the heterocycloalkyl component to the point of attachment.
• the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the heterocycloalkyl component and to the point of attachment.
• the alkyl component can include any number of carbons, such as C 0-6 , C 1-2 , C 1-3 , C 1 - 4 , C 1-5 , C 1-6 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
• the alkyl component can be absent.
• the heterocycloalkyl component is as defined above.
• “Aryl” means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
• an aryl group can have 6 to 20 carbon atoms, 6 to 14 carbon atoms, or 6 to 10 carbon atoms.
• Exemplary aryl groups include, but are not limited to, radicals derived from benzene (e.g., phenyl), naphthalene, anthracene, biphenyl, and the like.
• Alkyl-aryl refers to a radical having an alkyl component and an aryl component, where the alkyl component links the aryl component to the point of attachment.
• the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the aryl component and to the point of attachment.
• the alkyl component can include any number of carbons, such as C 0-6 , C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
• the alkyl component can be absent.
• the aryl component is as defined above. Examples of alkyl-aryl groups include, but are not limited to, benzyl and ethyl-benzene.
• Heteroaryl refers to an aromatic group, including groups having an aromatic tautomer or resonance structure, having a single ring, multiple rings, or multiple fused rings, with at least one heteroatom in the ring, i.e., one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the nitrogen or sulfur can be oxidized.
• the term includes rings having one or more annular O, N, S, S(O), S(O) 2 , and N-oxide groups.
• the term includes rings having one or more annular C(O) groups.
• heteroaryl include 5 to 20 ring atoms (i.e., 5- to 20-membered heteroaryl), 5 to 12 ring atoms (i.e., 5- to 12-membered heteroaryl), or 5 to 10 ring atoms (i.e., 5- to 10-membered heteroaryl), and 1 to 5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and oxidized forms of the heteroatoms.
• heteroaryl groups include, but are not limited to, pyridin-2(1H)-one, pyridazin- 3(2H)-one, pyrimidin-4(3H)-one, quinolin-2(1H)-one, pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl.
• Heteroaryl does not encompass or overlap with aryl as defined above.
• Alkyl-heteroaryl refers to a radical having an alkyl component and a heteroaryl component, where the alkyl component links the heteroaryl component to the point of attachment.
• the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the heteroaryl component and to the point of attachment.
• the alkyl component can include any number of carbons, such as C 0-6 , C 1-2 , C 1-3 , C 1-4 , C 1-5 , C 1-6 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 and C 5-6 .
• the alkyl component can be absent.
• the heteroaryl component is as defined within.
• KRAS G12D refers to the G12D mutation of the KRAS protein, where aspartic acid replaces glycine at amino acid position 12.
• KRAS G12D inhibitor refers to compounds of the present disclosure, including compounds of Formulas I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib- 5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), and (IIb-2).
• KRAS G12D-associated disease or disorder refers to diseases or disorders associated with or mediated by or having a KRAS G12D mutation. Representative diseases or disorders include, but are not limited to, KRAS G12D-associated cancer.
• “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, formulations, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
• the compounds described herein can be prepared and/or formulated as pharmaceutically acceptable salts or when appropriate as a free base.
• Pharmaceutically acceptable salts are non- toxic salts of a free base form of a compound that possess the desired pharmacological activity of the free base. These salts can be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen can be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid.
• Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates
• Examples of “pharmaceutically acceptable salts” of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX 4 + (wherein X is C1 ⁇ C4 alkyl). Also included are base addition salts, such as sodium or potassium salts.
• n is the number of hydrogen atoms in the molecule.
• the deuterium atom is a non-radioactive isotope of the hydrogen atom.
• Such compounds can increase resistance to metabolism, and thus can be useful for increasing the half- life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal.
• Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
• Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
• PET Positron Emission Topography
• the compounds of the embodiments disclosed herein, or their pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
• the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
• Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization.
• chirality is not specified but is present, it is understood that the embodiment is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s).
• scalemic mixture is a mixture of stereoisomers at a ratio other than 1:1.
• Racemates refers to a mixture of enantiomers. The mixture can comprise equal or unequal amounts of each enantiomer.
• Stepoisomer and “stereoisomers” refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
• the compounds can exist in stereoisomeric form if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures.
• the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of ADVANCED ORGANIC CHEMISTRY, 4th ed., J. March, John Wiley & Sons, New York, 1992).
• a “subject” or “patient” is meant to describe a human or vertebrate animal including a dog, cat, pocket pet, marmoset, horse, cow, pig, sheep, goat, elephant, giraffe, chicken, lion, monkey, owl, rat, squirrel, slender loris, and mouse.
• a “pocket pet” refers to a group of vertebrate animals capable of fitting into a commodious coat pocket such as, for example, hamsters, chinchillas, ferrets, rats, guinea pigs, gerbils, rabbits and sugar gliders.
• an “arylalkyl” group for example, can be attached to the remainder of the molecule at either an aryl or an alkyl portion of the group.
• a prefix such as “Cu- C v ” or “(C u -C v )” indicates that the following group has from u to v carbon atoms.
• C 1-6 alkyl and “C 1 -C 6 alkyl” both indicate that the alkyl group has from 1 to 6 carbon atoms.
• Beneficial or desired clinical results may include one or more of the following: (a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); (b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and/or (c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.
• inhibiting the disease or condition e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition
• terapéuticaally effective amount is the amount of compound disclosed herein present in a formulation described herein that is needed to provide a desired level of drug in the secretions and tissues of the airways and lungs, or alternatively, in the bloodstream of a subject to be treated to give an anticipated physiological response or desired biological effect when such a formulation is administered by the chosen route of administration.
• the precise amount will depend upon numerous factors, for example the particular compound disclosed herein, the specific activity of the formulation, the delivery device employed, the physical characteristics of the formulation, its intended use, as well as subject considerations such as severity of the disease state, subject cooperation, etc., and can readily be determined by one skilled in the art based upon the information provided herein.
• administering refers to oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.
• the administration can be carried out according to a schedule specifying frequency of administration, dose for administration, and other factors.
• Co-administration refers to administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents.
• a unit dose of a compound of the present disclosure is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents.
• a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the present disclosure within seconds or minutes.
• a unit dose of a compound of the present disclosure is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents.
• a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the present disclosure.
• Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of each agent are present in the body of the patient.
• Subject refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In some embodiments, the subject is a human.
• Disease or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
• the disease may be an autoimmune, inflammatory, cancer, infectious (e.g., a viral infection), metabolic, developmental, cardiovascular, liver, intestinal, endocrine, neurological, or other disease.
• the disease is cancer (e.g.
• lung cancer ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma).
• Cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas and sarcomas.
• Exemplary cancers that may be treated with a compound, pharmaceutical composition, or method provided herein include lymphoma, sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g. triple negative, ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g. hepatocellular carcinoma) , lung cancer (e.g.
• non- small cell lung carcinoma non- small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, glioma, melanoma, prostate cancer, castration-resistant prostate cancer, breast cancer, triple negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck, or esophagus), colorectal cancer, leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma.
• squamous cell carcinoma e.g., head, neck, or esophagus
• colorectal cancer leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma.
• Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, esophagus, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, end
• Leukemia refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non- increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
• Exemplary leukemias that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous
• “Sarcoma” generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
• Sarcomas that may be treated with a compound, pharmaceutical composition, or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial
• Melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
• Melanomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
• Carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
• Exemplary carcinomas that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basal oid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, ductal carcinoma, carcinoma durum
• Metalastasis can be used interchangeably and refer to the spread of a proliferative disease or disorder, e.g., cancer, from one organ or another non- adjacent organ or body part. Cancer occurs at an originating site, e.g., breast, which site is referred to as a primary tumor, e.g., primary breast cancer. Some cancer cells in the primary tumor or originating site acquire the ability to penetrate and infiltrate surrounding normal tissue in the local area and/or the ability to penetrate the walls of the lymphatic system or vascular system circulating through the system to other sites and tissues in the body. A second clinically detectable tumor formed from cancer cells of a primary tumor is referred to as a metastatic or secondary tumor.
• metastatic cancer refers to a disease in which a subject has or had a primary tumor and has one or more secondary tumors.
• non-metastatic cancer or subjects with cancer that is not metastatic refers to diseases in which subjects have a primary tumor but not one or more secondary tumors.
• metastatic lung cancer refers to a disease in a subject with or with a history of a primary lung tumor and with one or more secondary tumors at a second location or multiple locations, e.g., in the breast.
• Associated or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g., diabetes, cancer (e.g.
• prostate cancer renal cancer, metastatic cancer, melanoma, castration-resistant prostate cancer, breast cancer, triple negative breast cancer, glioblastoma, ovarian cancer, lung cancer, squamous cell carcinoma (e.g., head, neck, or esophagus), colorectal cancer, leukemia, acute myeloid leukemia, lymphoma, B cell lymphoma, or multiple myeloma)) means that the disease (e.g.
• lung cancer ovarian cancer, osteosarcoma, bladder cancer, cervical cancer, liver cancer, kidney cancer, skin cancer (e.g., Merkel cell carcinoma), testicular cancer, leukemia, lymphoma, head and neck cancer, colorectal cancer, prostate cancer, pancreatic cancer, melanoma, breast cancer, neuroblastoma) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function.
• adjacent carbons refers to consecutive carbons atoms that are directly attached to each other.
• “Prodrug” as used herein refers to a derivative of a drug that upon administration to the human body is converted to the parent drug according to some chemical or enzymatic pathway.
• “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and combinations thereof.
• the use of pharmaceutically acceptable carriers and pharmaceutically acceptable excipients for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic formulations is contemplated. Supplementary active ingredients can also be incorporated into the formulations.
• the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof.
• Compounds [0080] Disclosed herein are, among other things, compounds of Formulas I, I-A, II, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), (II-1), (IIa), (IIa- 1), (IIb), (IIb-1), and (IIb-2).
• the present disclosure provides a compound of Formula I: Formula I, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; R 1 , R 2 , R 3 , and R 4 are each independently H or C 1 -C 3 alkyl; L 1 is O, S, or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl; L 2 is CR 2
• the present disclosure provides the compound of Formula I, wherein R 1 , R 2 , R 3 , and R 4 are each independently H or methyl. In some embodiments, the present disclosure provides the compound of Formula I, wherein one of two of R 1 , R 2 , R 3 , and R 4 are methyl. In some embodiments, the present disclosure provides the compound of Formula I, wherein R 1 and R 2 are methyl. In some embodiments, the present disclosure provides the compound of Formula I, wherein R 1 , R 2 , R 3 , and R 4 are each H.
• the present disclosure provides a compound of Formula I-A: Formula I-A, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; L 1 is O, S, or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl; L 2 is CR 2a R 2b ; alternatively, L 2 is O or S, and L 1 is CR
• the present disclosure provides the compound of Formula I or I-A, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I-1): [0084] In some embodiments, the present disclosure provides the compound of Formula I, I-A, or I-1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I-2): [0085] In some embodiments, the present disclosure provides the compound of Formula I, I-A, or I-1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I-3): [0086] In some embodiments, the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein X is N.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein X is CH. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is (CH 2 ) m CN, and m is 0, 1, 2 or 3. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is CH 2 CN.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is halo.
• the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is O.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ia): [0088] In some embodiments, the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CHR 1b . In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CH 2 .
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CH(CH 3 ). In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1b are each independently H, C 1 -C 3 alkyl, or halo. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is C 1 -C 3 alkyl or halo.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is H or methyl. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is H. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is methyl.
• the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, or I-3, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ib): [0090] In some embodiments, the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 2a and R 2b are each independently H, C 1 -C 3 alkyl, halo, or C 1 -C 6 haloalkyl.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein L 2 is CHR 2b .
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 2b is H or C 1 -C 3 alkyl.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 2b is H.
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 2b is C 1 -C 3 alkyl. In some embodiments, the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 2b is methyl. [0091] In some embodiments, the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein L 3 is CR 3a R 3b .
• the present disclosure provides the compound of Formula I, I-A, I-1, I-2, I-3, (Ia), or (Ib), or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b are H.
• the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, I-3, or (Ia), or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ia-1):
• the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, I-3, or (Ib), or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ib-1):
• the present disclosure provides the compound of Formula I, I-A, I- 1, I-2, I-3, Ib, or Ib-1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (Ib-2): [0095]
• the present disclosure provides the compound of Formula I, I-A,
• the present disclosure provides a compound of Formula II: Formula II, or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is (CH 2 ) m CN or halo; m is 0, 1, 2 or 3; L 1 is O or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, -CN, C 1 -C 3 cyanoalkyl, or C 3 -C 6 cycloalkyl; alternatively, R 1a and R 1b can combine with the atom to which they are attached to form a C 3 -C 6 cycloalkyl; L 2 is CR 2a R 2b ; R 2a and R 2b are each independently H, C 1 -C 3 alkyl, C 1 -C
• the present disclosure provides the compound of Formula II, or a pharmaceutically acceptable salt thereof, having the structure of Formula (II-1): [0099] In some embodiments, the present disclosure provides the compound of Formula II or II- 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (II-2): [0100] In some embodiments, the present disclosure provides the compound of Formula II or II- 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (II-3): [0101] In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is N.
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is CH. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is (CH 2 ) m CN, and m is 0, 1, 2 or 3. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is CH 2 CN.
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is CR x , wherein R x is halo. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein X is C-Cl. [0102] In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is O.
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIa): [0103]
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CHR 1b .
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CH 2 .
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein L 1 is CH(CH 3 ).
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein R 1a and R 1b are each independently H, C 1 -C 3 alkyl, or halo. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is C 1 -C 3 alkyl or halo. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, wherein R 1b is methyl.
• the present disclosure provides the compound of Formula II, II-1, II-2, or II-3, or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIb): (IIb).
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein R 2a and R 2b are each independently H, C 1 -C 3 alkyl, halo, or C 1 -C 6 haloalkyl.
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein L 2 is CHR 2b .
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein R 2b is H or C 1 -C 3 alkyl.
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein R 2b is H.
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein R 2b is C 1 -C 3 alkyl. In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), or (IIb), or a pharmaceutically acceptable salt thereof, wherein R 2b is methyl.
• the present disclosure provides the compound of Formula II, II-1, II-2, II-3, or (IIa), or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIa-1): [0107] In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, II-3, or (IIb), or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIb-1): [0108] In some embodiments, the present disclosure provides the compound of Formula II, II-1, II-2, II-3, (IIa), (IIb), or (IIb-1), or a pharmaceutically acceptable salt thereof, having the structure of Formula (IIb-2): [0109] In some embodiments, the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa), (I
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), and (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is naphthyl substituted with 0, 1, 2, 3, 4, or 5 R A2 .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), and (IIb-2), or a pharmaceutically acceptable salt thereof, wherein each R A2 is independently C 1 -C 6 alkyl, -OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halo, C 1 -C 6 haloalkyl, -OR A2a , -SR A2a , or -(C 1 -C 6 alkyl)-(C 3 -C 8 cycloalkyl), wherein each alkenyl is substituted with 0, 1, 2, or 3 R A3 ; each R A2a is independently C 1 -C 6
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), and (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), and (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is [0115] In some embodiments, the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R B is H.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R B is -C(O)R B1 , or -C(O)OR B2 ; R B1 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 6 -C 14 aryl, or 5- to 14-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, C 6 -C 14 aryl or 5- to 14-membered heteroaryl are substituted with 0, 1, 2, or 3 R B1a ;
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is a bond.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is Y is C or Si; n is 0 or 1; q is 0 or 1; R Y1 is H or C 1 -C 3 alkyl; and R Y2 is H or C 1 -C 3 alkyl; alternatively, R Y1 and R Y2 combine to form a C 3 -C 6 cycloalkyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is Y is C or Si; n is 0 or 1; q is 0 or 1; R Y1 is H or Me; and R Y2 is H or Me; alternatively, R Y1 and R Y2 combine to form a cyclopropyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is Y is C; n is 0; q is 0; R Y1 is H; and R Y2 H.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is –CH 2 -.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is Y is C or Si; n is 1; q is 1; R Y1 is Me; and R Y2 is Me; alternatively, R Y1 and R Y2 combine to form a cyclopropyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R C is 3- to 7-membered heterocyclyl, substituted with 0, 1, or 2 R C3 ; and each R C3 is independently halo or C 1 -C 6 haloalkyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R 1b is H or methyl; R C3 is -CH 2 OR C3a1 or F; and R C3a1 is 5- to 6-membered heteroaryl substituted with one halo or C1-C2 haloalkyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib- 5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R 1b is H or methyl; and R C3 is F.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R 1b is H or methyl; R C3 is -CH 2 OR C3a1 ; and R C3a1 is 6-membered heteroaryl substituted with one C1 haloalkyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R 1b is H or methyl; R C3 is - CH 2 OR C3a1 ; and R C3a1 is pyridazine, pyrimidine, or pyrazine, wherein the pyridazine, pyrimidine, or pyrazine is substituted with one CF 3 .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is –CH 2 -; R C is 3- to 14- membered heterocyclyl substituted with 1 R C3 ; R C3 is C 1 -C 6 alkyl substituted with one -OR C3a1 or -SR C3a1 ; and R C3a1 is 5- to 10-membered heteroaryl substituted with 0, 1, or 2 C 1 -C 3 haloalkyl or C 1 -C 3 haloalkoxy.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa- 1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L C is –CH 2 -; R C is 4- to 8-membered heterocyclyl substituted with 1 R C3 ; R C3 is -CH 2 OR C3a1 ; and R C3a1 is a pyrimidine, wherein the pyrimidine is substituted with 1 trifluoromethyl group.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the –O-L C -R C moiety is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the –O-L C -R C moiety is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the –O-L C -R C moiety is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the –O-L C -R C moiety is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the –O-L C -R C moiety is [0132] In some embodiments, the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R D is F or Cl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R D is F.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or CR x ; R x is halo; L 1 is O or CR 1a R 1b ; R 1a and R 1b are each independently H, C 1 -C 3 alkyl, or halo; L 2 is CR 2a R 2b ; R 2a and R 2b are each independently H, C 1 -C 3 alkyl, C 1 -C 6 haloalkyl, or C 3 -C 6 cycloalkyl; L 3 is a bond or CR 3a R 3b ; R 3a and R 3b are each independently H or C 1 -C 3 alkyl; R 1 , R 2 , R 3 , and R 4 are each H; R A is naphthyl, wherein R A is substituted with 0, 1, 2, 3, 4, or 5 R A2
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt thereof, wherein X is N, CH, or C-Cl; L 1 is O, CH 2 , CHCH 3 , CHCH 2 CH 3 , CHF, or CF 2 ; L 2 is CH 2 , CHCH 3 , CHCH 2 CH 3 , CHCHF 2 , or L 3 is a bond, CH 2 , or CHCH 3 ; R 1 , R 2 , R 3 , and R 4 are each H; R A is R B is H; the –O-L C -R C moiety is
• R D is F.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L 1 is CH 2 , CHCH 3 , CHCH 2 CH 3 , CHF, or CF 2 .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein L 3 is CH 2 or CHCH 3 .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R A is
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt thereof, wherein X is N; R 1 , R 2 , R 3 , and R 4 are each H; L 1 is CR 1a R 1b ; R 1a and R 1b are each independently H or C 1 -C 3 alkyl; L 2 is CR 2a R 2b ; R 2a and R 2b are each H; L 3 is CR 3a R 3b ; R 3a and R 3b are each H; R A is naphthyl, wherein R A is substituted with 2 R A2 ; each R A2 is independently C 2 -C 6 alkynyl or halo; R B is H; L C is ; Y is C; n is 0; q is 0; R Y1 is H; R Y2 is H; R C is 3- to 14-membered heterocyclyl, wherein the
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), or (I-3), or a pharmaceutically acceptable salt thereof, wherein X is N; R 1 , R 2 , R 3 , and R 4 are each H; L 1 is CH 2 or CHCH 3 ; L 2 is CH 2 ; L 3 is CH 2 ; R A is R B is H; the -O-L C -R C moiety is [0140] In some embodiments, the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula (Ib-5) or Formula (Ib-6): wherein the compound has the structure of Formula
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), II, (II-1), (IIa), (IIa-1), (IIb), (IIb- 1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula (Ib-7) or Formula (Ib-8): wherein R 1b is H or methyl; R C3 is -CH 2 OR C3a1 or F; and R C3a1 is 5- to 6-membered heteroaryl substituted with one halo or C 1 -C 2 haloalkyl.
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), wherein the compound has the structure: .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), wherein the compound has the structure: .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: .
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), wherein the compound has the structure:
• the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: [0150] In some embodiments, the present disclosure provides the compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (Ib-3), (Ib-4
• novel and unobvious compounds produced by a process comprising contacting a compound with a mammal for a period of time sufficient to yield a metabolic product thereof.
• Such products typically are identified by preparing a radiolabelled (e.g., 14 C or 3 H) compound, administering it parenterally in a detectable dose (e.g., greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig, monkey, or to man, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours) and isolating its conversion products from the urine, blood or other biological samples.
• a detectable dose e.g., greater than about 0.5 mg/kg
• an animal such as rat, mouse, guinea pig, monkey, or to man
• sufficient time for metabolism to occur typically about 30 seconds to 30 hours
• isolating its conversion products from the urine, blood or other biological samples typically isolating its conversion products from the urine, blood or other biological samples.
• the metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis.
• the prodrugs typically will be stable in the digestive system but may be substantially hydrolyzed to the parental drug in the digestive lumen, liver, lung or other metabolic organ, or within cells in general.
• a prodrug is understood to be a compound that is chemically designed to efficiently liberate the parent drug after overcoming biological barriers to oral delivery. IV.
• compositions comprising a pharmaceutically effective amount of a compound of the present disclosure (e.g., a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II- 1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2),) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
• a compound of the present disclosure e.g., a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (I
• a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
• the compounds disclosed herein can be formulated with conventional carriers and excipients. Tablets can contain, for instance, excipients, glidants, fillers, binders, or a combination thereof.
• Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic.
• Exemplary excipients include, but are not limited to, those set forth in the “HANDBOOK OF PHARMACEUTICAL EXCIPIENTS” (1986).
• Excipients can include, for example, ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid, and combinations thereof.
• the formulation is basic.
• the formulation is acidic.
• the formulation has a neutral pH.
• the pH of the formulations is from 2 to 11 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 5-6, 5-7, 5-8, 5-9, 5-10, 5-11, 6-7, 6-8, 6-9, 6-10, 6-11, 7-8, 7-9, 7-10, 7-11, 8-9, 8-10, 8-11, 9-10, or 9-11).
• 2 to 11 e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 4-11, 5-6, 5-7, 5-8, 5-9, 5-10,
• the compounds disclosed herein have pharmacokinetic properties (e.g., oral bioavailability) suitable for oral administration of the compounds.
• Formulations suitable for oral administration can, for instance, be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
• the active ingredient can also be administered, for instance, as a bolus, electuary, or paste.
• a tablet can be made by compression or molding, optionally with at least accessory ingredients.
• Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as, for instance, a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active, dispersing agent, or a combination thereof. Molded tablets can be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets can optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.
• a powder or granules optionally mixed with a binder, lubricant, inert diluent, preservative, surface active, dispersing agent, or a combination thereof.
• Molded tablets can be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
• the tablets can optionally be coated or
• the formulations can be applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range from 0.1% to 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), from 0.2% to 15% w/w, or from 0.5% to 10% w/w.
• the active ingredients can be employed in some embodiments with either a paraffinic or a water-miscible ointment base.
• the active ingredients can be formulated in a cream with an oil-in-water cream base.
• the aqueous phase of the cream base can include, for example, from 30% to 90% (e.g., 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%) w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
• a polyhydric alcohol i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof.
• the cream base can include, for instance, a compound that enhances absorption or penetration of the active ingredient through the skin or other affected areas.
• Examples of such dermal penetration enhancers include, but are not limited to, dimethyl sulfoxide and related analogs.
• the cream or emulsion does not include water.
• the oily phase of the emulsions can be constituted from known ingredients in a known manner.
• the phase comprises merely an emulsifier (otherwise known as an emulgent).
• the phase comprises a mixture of at least one emulsifier with a fat, an oil, or a combination thereof.
• a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer.
• the emulsifier(s) with or without stabilizer(s) can make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base that can form the oily dispersed phase of the cream formulations.
• Emulgents and emulsion stabilizers suitable for use in the formulation can include, but are not limited to, TWEEN ® 60, TWEEN® 80, SPAN ® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate, sodium lauryl sulfate, and combinations thereof.
• the choice of suitable oils or fats for the formulation can be based on achieving the desired cosmetic properties.
• the cream can be a non-greasy, non-staining, and washable product with suitable consistency to avoid leakage from tubes or other containers.
• esters can be included, such as, for example, straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2- ethylhexyl palmitate, a blend of branched chain esters known as CRODAMOL® CAP, or a combination thereof.
• high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be included.
• the compounds disclosed herein are administered in pharmaceutical compositions.
• the pharmaceutical compositions are for veterinary use.
• the pharmaceutical compositions are for human use.
• the pharmaceutical compositions disclosed herein include at least one additional therapeutic agent.
• the pharmaceutical compositions disclosed herein include one or more additional therapeutic agent.
• the one or more additional therapeutic agents is independently a chemotherapeutic agent, an immunotherapeutic agent, a hormonal agent, an anti-hormonal agent, a targeted therapy agent, or an anti-angiogenesis agent.
• Pharmaceutical compositions disclosed herein can be in any form suitable for the intended method of administration.
• compositions disclosed herein can be presented in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy. Exemplary techniques and formulations can be found, for instance, in REMINGTON’S PHARMACEUTICAL SCIENCES (Mack Publishing Co., Easton, PA). Such methods can include the step of bringing into association a compound disclosed herein with the carrier that constitutes at least accessory ingredients. In general, the formulations can be prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
• tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, solutions, syrups or elixirs can be prepared.
• Formulations intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such formulations can contain at least agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
• excipients can be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets can be uncoated or can be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax can be employed.
• inert diluents such as calcium or sodium carbonate, lactose, calcium or sodium phosphate
• granulating and disintegrating agents such as maize starch, or alginic acid
• binding agents such as starch, ge
• Formulations for oral use can be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin, or olive oil.
• an inert solid diluent for example calcium phosphate or kaolin
• soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin, or olive oil.
• Aqueous suspensions can contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
• Such excipients can include, for instance, a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally-occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
• a suspending agent such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium al
• the aqueous suspension can also contain, for example, at least preservatives such as ethyl or n- propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents, one or more sweetening agents (such as sucrose or saccharin), or combinations thereof.
• suspending agents include cyclodextrin.
• the suspending agent is sulfobutyl ether beta-cyclodextrin (SEB-beta-CD), for example CAPTISOL ® .
• Oil suspensions can be formulated by suspending the active ingredient in a vegetable oil (e.g., arachis oil, olive oil, sesame oil, coconut oil, or a combination thereof), a mineral oil such as liquid paraffin, or a combination thereof.
• the oral suspensions can contain, for instance, a thickening agent, such as beeswax, hard paraffin, cetyl alcohol, or a combination thereof.
• sweetening agents such as those set forth above, and/or flavoring agents, are added to provide a palatable oral preparation.
• the formulations disclosed herein are preserved by the addition of an antioxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water can provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, a preservative, and combinations thereof. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
• the pharmaceutical compositions can also be in the form of oil-in-water emulsions.
• the oily phase can be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
• Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally-occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
• the emulsion can also contain sweetening and flavoring agents. Syrups and elixirs can be formulated with sweetening agents, such as for instance, glycerol, sorbitol or sucrose.
• compositions can also contain, for instance, a demulcent, a preservative, a flavoring, a coloring agent, or a combination thereof.
• the pharmaceutical compositions can be in the form of a sterile injectable or intravenous preparation, such as a sterile injectable aqueous or oleaginous suspension.
• This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
• the sterile injectable or intravenous preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
• the acceptable vehicles and solvents that can be employed are water, Ringer’s solution and isotonic sodium chloride solution.
• sterile fixed oils can be employed as a solvent or suspending medium.
• any bland fixed oil can be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid can likewise be used in the preparation of injectables.
• the acceptable vehicles and solvents include, but are not limited to, water, Ringer’s solution isotonic sodium chloride solution, and hypertonic sodium chloride solution.
• a time-release formulation intended for oral administration to humans can contain approximately 1 mg to 2000 mg of active material compounded with an appropriate and convenient amount of carrier material, which can vary from 5% to 95% of the total formulations (weight:weight).
• a time-release formulation intended for oral administration to humans can contain approximately 1 mg to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material, which can vary from 5% to 95% of the total formulations (weight:weight).
• the pharmaceutical composition can be prepared to provide easily measurable amounts for administration.
• an aqueous solution intended for intravenous infusion can contain from 3 ⁇ g to 500 ⁇ g of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of 30 mL/hr can occur.
• Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
• the compounds disclosed herein are included in the pharmaceutical compositions disclosed herein in a concentration of 0.5% to 20% (e.g., 0.5% to 10%, 1.5% w/w).
• Formulations suitable for topical administration in the mouth include lozenges can comprise an active ingredient (i.e., a compound disclosed herein and/or additional therapeutic agents) in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• an active ingredient i.e., a compound disclosed herein and/or additional therapeutic agents
• pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia
• mouthwashes comprising the active ingredient in a suitable liquid carrier.
• Formulations for rectal administration can be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
• Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
• Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that can contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non- aqueous sterile suspensions that can include suspending agents and thickening agents.
• the formulations can be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately before use.
• sterile liquid carrier for example water for injection
• Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
• Preferred unit-dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the active ingredient.
• formulations can include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration can include flavoring agents.
• veterinary formulations comprising a compound disclosed herein together with a veterinary carrier therefor.
• Veterinary carriers are materials useful for the purpose of administering the formulation and can be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary formulations can be administered orally, parenterally, or by any other desired route.
• Controlled release formulations in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given active ingredient.
• Effective dose of active ingredient depends at least on the nature of the condition being treated, toxicity, whether the compound is being used prophylactically (lower doses) or against an active viral infection, the method of delivery, and the pharmaceutical composition, and will be determined by the clinician using conventional dose escalation studies.
• the effective dose is from 0.0001 to 100 mg/kg body weight per day; for instance, from 10 to 30 mg/kg body weight per day; from 15 to 25 mg/kg body weight per day; from 10 to 15 mg/kg body weight per day; or from 20 to 30 mg/kg body weight per day.
• the daily candidate dose for an adult human of approximately 70 kg body weight can range from 1 mg to 2000 mg (e.g., from 5 mg to 500 mg, from 500 mg to 1000 mg, from 1000 mg to 1500 mg, from 1500 mg to 2000 mg), and can take the form of single or multiple doses.
• kits that includes a compound disclosed herein or a pharmaceutically acceptable salt thereof.
• the kits described herein can comprise a label and/or instructions for use of the compound in the treatment of a disease or condition in a subject (e.g., human) in need thereof.
• the disease or condition is viral infection.
• the kit can also comprise one or more additional therapeutic agents and/or instructions for use of additional therapeutic agents in combination with the compound disclosed herein in the treatment of the disease or condition in a subject (e.g., human) in need thereof.
• the kits provided herein comprise individual dose units of a compound as described herein, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate or solvate thereof.
• kits can contain pills, tablets, capsules, prefilled syringes or syringe cartridges, IV bags, inhalers, nebulizers etc., each comprising a therapeutically effective amount of the compound in question, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, tautomer, polymorph, pseudopolymorph, amorphous form, hydrate or solvate thereof.
• the kit can contain a single dosage unit and in others multiple dosage units are present, such as the number of dosage units required for a specified regimen or period.
• articles of manufacture that include a compound disclosed herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or tautomer thereof; and a container.
• the container of the article of manufacture is a vial, jar, ampoule, preloaded syringe, blister package, tin, can, bottle, box, an intravenous bag, an inhaler, or a nebulizer.
• Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the route may vary with for example the condition of the recipient. An advantage of the compounds herein is that they are orally bioavailable and can be dosed orally. [0190]
• the compounds of the present disclosure (also referred to herein as the active ingredients), can be administered by any route appropriate to the condition to be treated.
• Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the route may vary with for example the condition of the recipient. An advantage of certain compounds disclosed herein is that they are orally bioavailable and can be dosed orally.
• a compound of the present disclosure may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer.
• the compound is administered on a daily or intermittent schedule for the duration of the individual’s life.
• the dosage or dosing frequency of a compound of the present disclosure may be adjusted over the course of the treatment, based on the judgment of the administering physician.
• the compound may be administered to an individual (e.g., a human) in an effective amount. In some embodiments, the compound is administered once daily.
• the compound can be administered by any useful route and means, such as by oral or parenteral (e.g., intravenous) administration.
• Therapeutically effective amounts of the compound may include from about 0.00001 mg/kg body weight per day to about 10 mg/kg body weight per day, such as from about 0.0001 mg/kg body weight per day to about 10 mg/kg body weight per day, or such as from about 0.001 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.01 mg/kg body weight per day to about 1 mg/kg body weight per day, or such as from about 0.05 mg/kg body weight per day to about 0.5 mg/kg body weight per day, or such as from about 0.3 mg to about 30 mg per day, or such as from about 30 mg to about 300 mg per day.
• a compound of the present disclosure may be combined with one or more additional therapeutic agents in any dosage amount of the compound of the present disclosure (e.g., from about 1 mg to about 1000 mg of compound).
• Therapeutically effective amounts may include from about 1 mg per dose to about 1000 mg per dose, such as from about 50 mg per dose to about 500 mg per dose, or such as from about 100 mg per dose to about 400 mg per dose, or such as from about 150 mg per dose to about 350 mg per dose, or such as from about 200 mg per dose to about 300 mg per dose.
• therapeutically effective amounts of the compound of the present disclosure are about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, about 475, or about 500 mg per dose.
• Other therapeutically effective amounts of the compound of the present disclosure are about 100 mg per dose, or about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 425, about 450, or about 500 mg per dose.
• a single dose can be administered hourly, daily, or weekly.
• a single dose can be administered once about every 1 hour, about 2, about 3, about 4, about 6, about 8, about 12, about 16 or once about every 24 hours.
• a single dose can also be administered once about every 1 day, about 2, about 3, about 4, about 5, about 6, or once about every 7 days.
• a single dose can also be administered once about every 1 week, about 2, about 3, or once about every 4 weeks.
• a single dose can be administered once about every week.
• a single dose can also be administered once about every month.
• Other therapeutically effective amounts of the compound of the present disclosure are about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, or about 100 mg per dose.
• the frequency of dosage of the compound of the present disclosure can be determined by the needs of the individual patient and can be, for example, once per day or twice, or more times, per day. Administration of the compound continues for as long as necessary to treat the disease or condition.
• a compound can be administered to a human having cancer for a period of from about 20 days to about 180 days or, for example, for a period of from about 20 days to about 90 days or, for example, for a period of from about 30 days to about 60 days.
• Administration can be intermittent, with a period of several or more days during which a patient receives a daily dose of the compound of the present disclosure followed by a period of several or more days during which a patient does not receive a daily dose of the compound.
• a patient can receive a dose of the compound every other day, or three times per week.
• a patient can receive a dose of the compound each day for a period of from about 1 to about 14 days, followed by a period of about 7 to about 21 days during which the patient does not receive a dose of the compound, followed by a subsequent period (e.g., from about 1 to about 14 days) during which the patient again receives a daily dose of the compound.
• Alternating periods of administration of the compound, followed by non-administration of the compound can be repeated as clinically required to treat the patient.
• compositions comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents, and a pharmaceutically acceptable excipient are provided.
• kits comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, in combination with one or more (e.g., one, two, three, four, one or two, one to three, or one to four) additional therapeutic agents are provided.
• a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with one, two, three, four or more additional therapeutic agents.
• a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is combined with two additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with three additional therapeutic agents. In some embodiments, a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is combined with four additional therapeutic agents.
• the one, two, three, four or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and/or they can be selected from different classes of therapeutic agents. [0203] In some embodiments, when a compound of the present disclosure is combined with one or more additional therapeutic agents as described herein, the components of the composition are administered as a simultaneous or sequential regimen.
• a compound of the present disclosure When administered sequentially, the combination may be administered in two or more administrations.
• a compound of the present disclosure is combined with one or more additional therapeutic agents in a unitary dosage form for simultaneous administration to a patient, for example as a solid dosage form for oral administration.
• a compound of the present disclosure is co-administered with one or more additional therapeutic agents.
• the rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form.
• delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending a compound in an oil vehicle.
• injectable depot forms are made by forming microencapsule matrices of a compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).
• Depot injectable formulations are also prepared by entrapping a compound in liposomes or microemulsions that are compatible with body tissues. VII. Methods of Use [0207] The disclosure further relates to the use of compounds disclosed herein for the treatment and/or prophylaxis of diseases and/or conditions through inhibition of KRAS G12D and/or G12C. Further, the present disclosure relates to the use of said compounds for the preparation of a medicament for the treatment and/or prophylaxis of cancer. [0208] Medicaments as referred to herein can be prepared by conventional processes, including the combination of a compound according to the present disclosure and a pharmaceutically acceptable carrier.
• a method of inhibiting KRAS G12D protein in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib- 2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib- 5), (Ib-6), (Ib-7), (Ib-8
• provided herein is treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula I, I-A, (I-1), (I- 2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa)
• provided herein is a method of treating and/or preventing a cancer.
• a method of treating and/or preventing a KRAS G12D-associated cancer comprising contacting the cell with a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2).
• the KRAS G12D associated disease or condition includes cancer.
• the cancer is a hematological cancer.
• the cancer includes a solid tumor.
• the cancer includes a malignant tumor.
• the cancer includes a metastatic cancer.
• the cancer is resistant or refractory to one or more anticancer therapies.
• greater than about 50% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so-called “hot” cancer or tumor).
• greater than about 1% and less than about 50% of the cancer cells detectably express one or more cell surface immune checkpoint receptors (e.g., so called “warm” cancer or tumor).
• the KRAS G12D associated disease or condition is a hematological cancer, e.g., a leukemia (e.g., Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), B-cell ALL, Myelodysplastic Syndrome (MDS), myeloproliferative disease (MPD), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), undifferentiated leukemia), a lymphoma (e.g., small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLB
• AML Acute Myelogenous Leukemia
• ALL Acute Lymphoblastic Leukemia
• MDS Myelodysplastic Syndrome
• MPD myeloproliferative disease
• the KRAS G12D associated disease or condition is an epithelial tumor (e.g., a carcinoma, a squamous cell carcinoma, a basal cell carcinoma, a squamous intraepithelial neoplasia), a glandular tumor (e.g., an adenocarcinoma, an adenoma, an adenomyoma), a mesenchymal or soft tissue tumor (e.g., a sarcoma, a rhabdomyosarcoma, a leiomyosarcoma, a liposarcoma, a fibrosarcoma, a dermatofibrosarcoma, a neurofibrosarcoma, a fibrous histiocytoma, an angiosarcoma, an angiomyxoma, a leiomyoma, a chondroma, a chondrosarcoma,
• an epithelial tumor
• the KRAS G12D associated disease or condition includes a solid tumor in or arising from a tissue or organ, such as: • bone (e.g., adamantinoma, aneurysmal bone cysts, angiosarcoma, chondroblastoma, chondroma, chondromyxoid fibroma, chondrosarcoma, chordoma, dedifferentiated chondrosarcoma, enchondroma, epithelioid hemangioendothelioma, fibrous dysplasia of the bone, giant cell tumor of bone, haemangiomas and related lesions, osteoblastoma, osteochondroma, osteosarcoma, osteoid osteoma, osteoma, periosteal chondroma, Desmoid tumor, Ewing sarcoma); • lips and oral cavity (e.g., odontogenic ameloblastoma, oral leukop
• the KRAS G12D associated disease or condition is a cancer selected from a lung cancer, a colorectal cancer, a breast cancer, a prostate cancer, a cervical cancer, a pancreatic cancer and a head and neck cancer.
• the cancer is metastatic.
• the KRAS G12D associated disease or condition is a cancer selected from non-small lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, and gastrointestinal stromal tumor (GIST).
• the cancer is metastatic.
• the KRAS G12D associated disease or condition is a cancer of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, uterine cancer, gastric cancer, bile duct cancer, testicular cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small cell lung cancer, small-cell lung cancer, myelodysplastic syndrome, thyroid cancer, or colon cancer.
• the KRAS G12D associated disease or condition is a cancer of pancreatic cancer, colorectal cancer, non-small cell lung cancer, endometrial cancer, uterine endometrical carcinoma, cholangio carcinoma, testicular germ cell cancer, cervical squamous carcinoma, or myelodysplastic syndrome.
• the cancer is or myelodysplastic syndrome.
• the cancer is high risk myelodysplastic syndrome or low risk myelodysplastic syndrome.
• the cancer is high risk myelodysplastic syndrome .
• the cancer is high risk myelodysplastic syndrome .
• the cancer is colorectal cancer. In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is endometrial cancer. In some embodiments, the cancer is uterine endometrical carcinoma. In some embodiments, the cancer is testicular germ cell cancer. In some embodiments, the cancer is cervical squamous carcinoma. In some embodiments, the cancer is cholangio carcinoma. [0224]
• the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
• the compounds of the present disclosure are administered at a daily dosage of from about 0.1 milligram to about 300 milligram per kilogram of animal body weight.
• the compounds of the present disclosure are given as a single daily dose or in divided doses two to six times a day, or in sustained release form.
• the total daily dosage is from about 1 milligram to about 1000 milligrams, or from about 1 milligram to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.1 milligrams to about 200 milligrams.
• the total daily dosage is from about 1 milligram to about 900 milligrams, about 1 milligram to about 800 milligrams, about 1 milligram to about 700 milligrams, about 1 milligram to about 600 milligrams, about 1 milligram to about 400 milligrams, about 1 milligram to about 300 milligrams, about 1 milligram to about 200 milligrams, about 1 milligram to about 100 milligrams, about 1 milligram to about 50 milligrams, about 1 milligram to about 20 milligram, or about 1 milligram to about 10 milligrams.
• the compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. Treatment cycles are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous. [0227] In some embodiments, the methods provided herein comprise administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved.
• Increments of about 5, 10, 25, 50, or 100 mg can be used to increase the dose.
• the dosage can be increased daily, every other day, twice per week, or once per week.
• the compound or pharmaceutically acceptable salt thereof of the present disclosure is administered in combination with one or more additional therapeutic agent or therapeutic modality.
• the present disclosure provides the pharmaceutical composition or the method wherein the one or more more additional therapeutic agent or additional therapeutic modality comprises one, two, three, or four additional therapeutic agents and/or therapeutic modalities.
• the present disclosure provides the pharmaceutical composition or the method wherein the additional therapeutic agent or therapeutic modalities are selected from an immune checkpoint modulator, an antibody-drug conjugate (ADC), an antiapoptotic agent, a targeted anticancer therapeutic, a chemotherapeutic agent, surgery, or radiation therapy.
• the additional therapeutic agent or therapeutic modalities are selected from an immune checkpoint modulator, an antibody-drug conjugate (ADC), an antiapoptotic agent, a targeted anticancer therapeutic, a chemotherapeutic agent, surgery, or radiation therapy.
• the present disclosure provides the pharmaceutical composition or the method wherein the immune checkpoint modulator is selected from an anti-PD-(L)1 antibody, an anti-TIGIT antibody, an anti-CTLA4 antibody, an anti-CCR8 antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, a CD47 inhibitor, a DGK ⁇ inhibitor, an HPK1 inhibitor, a FLT3 agonist, an adenosine receptor antagonist, a CD39 inhibitor, a CD73 inhibitor, an IL-2 variant (IL-2v), and a CAR-T cell therapy.
• the immune checkpoint modulator is selected from an anti-PD-(L)1 antibody, an anti-TIGIT antibody, an anti-CTLA4 antibody, an anti-CCR8 antibody, an anti-TREM1 antibody, an anti-TREM2 antibody, a CD47 inhibitor, a DGK ⁇ inhibitor, an HPK1 inhibitor, a FLT3 agonist, an adenosine receptor antagonist, a CD39 inhibitor, a CD73 inhibitor,
• the present disclosure provides the pharmaceutical composition or the method wherein the anti-PD-(L)1 antibody is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab, spartalizumab, atezolizumab, avelumab, durvalumab, cosibelimab, sasanlimab, tislelizumab, retifanlimab, balstilimab, toripalimab, cetrelimab, genolimzumab, prolgolimab, lodapolimab, camrelizumab, budigalimab, avelumab, dostarlimab, envafolimab, sintilimab, and zimberelimab.
• the anti-PD-(L)1 antibody is selected from pembrolizumab, nivolumab, cemiplimab, pidilizumab
• the present disclosure provides the pharmaceutical composition or the method wherein the anti-TIGIT antibody is selected from tiragolumab, vibostolimab, domvanalimab, AB308, AK127, BMS-986207, and etigilimab.
• the present disclosure provides the pharmaceutical composition or the method wherein the anti-CTLA4 antibody is selected from ipilimumab, tremelimumab, and zalifrelimab.
• the present disclosure provides the pharmaceutical composition or the method wherein the CD47 inhibitor is selected from magrolimab, letaplimab, lemzoparlimab, AL-008, RRx-001, CTX-5861, FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, and Q-1801.
• the present disclosure provides the pharmaceutical composition or the method wherein the adenosine receptor antagonist is etrumadenant (AB928), taminadenant, TT-10, TT-4, or M1069.
• the present disclosure provides the pharmaceutical composition or the method wherein the CD39 inhibitor is TTX-030.
• the present disclosure provides the pharmaceutical composition or the method wherein the CD73 inhibitor is quemliclustat (AB680), uliledlimab, mupadolimab, ORIC-533, ATG-037, PT-199, AK131, NZV930, BMS-986179, or oleclumab.
• the present disclosure provides the pharmaceutical composition or the method wherein the IL-2v is aldesleukin (Proleukin), bempegaldesleukin (NKTR-214), nemvaleukin alfa (ALKS-4230), THOR-202 (SAR-444245), BNT-151, ANV-419, XTX-202, RG-6279 (RO-7284755), NL-201, STK-012, SHR-1916, or GS-4528.
• the IL-2v is aldesleukin (Proleukin), bempegaldesleukin (NKTR-214), nemvaleukin alfa (ALKS-4230), THOR-202 (SAR-444245), BNT-151, ANV-419, XTX-202, RG-6279 (RO-7284755), NL-201, STK-012, SHR-1916, or GS-4528.
• the present disclosure provides the pharmaceutical composition or the method wherein the ADC is selected from sacituzumab govitecan, datopotamab deruxtecan, enfortumab vedotin, and trastuzumab deruxtecan.
• the present disclosure provides the pharmaceutical composition or the method wherein the additional therapeutic agent is selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, GS- 1811 (JTX-1811), quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, axicabtagene ciloleucel and brexucabtagene autoleucel.
• the additional therapeutic agent is selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS-3583, zimberelimab, GS-4224, GS-9716, GS-6451, GS- 1811 (JTX-1811), quemliclustat (AB680
• the method includes administering one or more additional therapeutic agents.
• the one or more additional therapeutic agents can be one or more therapuetic agents as described below.
• the one or more additional therapeutic agents is independently a chemotherapeutic agent, an immunotherapeutic agent, a hormonal agent, an anti-hormonal agent, a targeted therapy agent, or an anti-angiogenesis agent.
• the one or more additional therapeutic agents includes therapeutic agents used to treat high risk myelodysplastic syndrome (HR MDS), low risk myelodyplastic syndrome (LR MDS), colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, or endometrial cancer.
• the one or more additional therapeutic agents includes therapeutic agents used to treat high risk myelodysplastic syndrome (HR MDS).
• the one or more additional therapeutic agents includes azacitidine (Vidaza®), decitabine (Dacogen®), lenalidomide (Revlimid®), cytarabine, idarubicin, daunorubicin, cytarabine + daunorubicin, cytarabine + idarubicin, pevonedistat, venetoclax, sabatolimab, guadecitabine, rigosertib, ivosidenib, enasidenib, selinexor, BGB324, DSP-7888, or SNS-301.
• the one or more additional therapeutic agents includes therapeutic agents used to treat low risk myelodyplastic syndrome (LR MDS). In some embodiments, the one or more additional therapeutic agents includes lenalidomide, azacytidine, roxadustat, luspatercept, imetelstat, LB-100, or rigosertib. [0245] In some embodiments, the one or more additional therapeutic agents includes therapeutic agents used to treat colorectal cancer.
• LR MDS low risk myelodyplastic syndrome
• the one or more additional therapeutic agents includes lenalidomide, azacytidine, roxadustat, luspatercept, imetelstat, LB-100, or rigosertib.
• the one or more additional therapeutic agents includes therapeutic agents used to treat colorectal cancer.
• the one or more additional therapeutic agents includes bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, bevacizumab (Avastin ® ), leucovorin, 5- FU, oxaliplatin (FOLFOX), pembrolizumab (Keytruda ® ), FOLFIRI, regorafenib (Stivarga ® ), aflibercept (Zaltrap ® ), cetuximab (Erbitux ® ), Lonsurf (Orcantas ® ), XELOX, FOLFOXIRI, bevacizumab + leucovorin + 5-FU + oxaliplatin (FOLFOX), bevacizumab + FOLFIRI, bevacizumab + FOLFOX, aflibercept
• the one or more additional therapeutic agents includes therapeutic agents used to treat non-small cell lung cancer (NSCLC).
• the one or more additional therapeutic agents includes afatinib, albumin-bound paclitaxel, alectinib, atezolizumab, bevacizumab, bevacizumab, cabozantinib, carboplatin, cisplatin, crizotinib, dabrafenib, docetaxel, erlotinib, etoposide, gemcitabine, nivolumab, paclitaxel, pembrolizumab, pemetrexed, ramucirumab, trametinib, trastuzumab, vandetanib, vemurafenib, vinblastine, vinorelbine, alectinib (Alecensa ® ), dabrafenib (Tafinlar ® ), tram
• the one or more additional therapeutic agents includes therapeutic agents used to treat pancreatic cancer.
• the one or more additional therapeutic agents includes 5-FU, leucovorin, oxaliplatin, irinotecan, gemcitabine, nab-paclitaxel (Abraxane ® ), FOLFIRINOX, 5-FU + leucovorin + oxaliplatin + irinotecan, 5-FU + nanoliposomal irinotecan, leucovorin + nanoliposomal irinotecan, or gemcitabine + nab-paclitaxel.
• the one or more additional therapeutic agents includes therapeutic agents used to treat endometrial cancer.
• the one or more additional therapeutic agents includes carboplatin, paclitaxel, cisplatin, doxorubicin, ifosfamide, progesterone, anastrozole (Arimidex ® ), letrozole (Femara ® ), exemestane (Aromasin ® ), pembrolizumab (Keytruda ® ), lenvatinib (Lenvima ® ), or dostarlimab (Jemperli ® ).
• the one or more additional therapeutic agents is independently SNS-301, 5-FU + leucovorin + oxaliplatin + irinotecan, 5-FU + nanoliposomal irinotecan, 5-FU, afatinib (Gilotrif ® ), aflibercept (Zaltrap ® ), aflibercept + FOLFIRI, albumin-bound paclitaxel, alectinib (Alecensa ® ), anastrozole (Arimidex ® ), atezolizumab, avelumab, azacitidine (Vidaza®), bevacizumab (Avastin ® ), bevacizumab + carboplatin + nab-paclitaxel, bevacizumab + carboplatin + pemetrexed, bevacizumab + FOLFIRI, bevacizumab + FOLFOX, bevacizumab
• the present disclosure provides a method for manufacturing a medicament for treating cancer in a subject in need thereof, characterized in that a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, is used.
• the present disclosure provides a method for manufacturing a medicament for inhibiting cancer metastasis in a subject in need thereof, characterized in that a compound of the present invention, or a pharmaceutically acceptable salt thereof, is used.
• the present disclosure provides use of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer in a subject.
• the present disclosure provides use of the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting cancer metastasis in a subject.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject in need thereof.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in inhibiting cancer metastasis in a subject in need thereof.
• the present disclosure provides the compound of the present disclosure, or a pharmaceutically acceptable salt thereof, for use in therapy. VIII.
• the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents.
• the one or more additional therapeutic agents are one additional therapeutic agent. In some embodiments, the one or more additional therapeutic agents are two additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are three additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are four additional therapeutic agents.
• the pharmaceutical compositions provided herein have a compound of Formula I, I-A, (I-1), (I-2), (I-3), (Ia), (Ia-1), (Ib), (Ib-1), (Ib-2), (Ib-3), (Ib-4), (Ib-5), (Ib-6), (Ib-7), (Ib-8), II, (II-1), (IIa), (IIa-1), (IIb), (IIb-1), or (IIb-2), provided herein, or pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.
• the one or more additional therapeutic agents are one, two, three, or four additional therapeutic agents.
• the one or more additional therapeutic agents are one additional therapeutic agent.
• the one or more additional therapeutic agents are two additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are three additional therapeutic agents. In some embodiments, the one or more additional therapeutic agents are four additional therapeutic agents. [0259] In some embodiments the additional therapeutic agent includes, e.g., an inhibitory immune checkpoint blocker or inhibitor, a stimulatory immune checkpoint stimulator, agonist or activator, a chemotherapeutic agent, an anti-cancer agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-proliferation agent, an anti-angiogenic agent, an anti-inflammatory agent, an immunotherapeutic agent, a therapeutic antigen-binding molecule (e.g., a mono- and multi- specific antibody, or fragment thereof, in any format, such as DART®, Duobody®, BiTE®, BiKE, TriKE, XmAb®, TandAb®, scFv, Fab, Fab derivative), a bi-specific antibody, a non- immunoglobulin
• the one or more additional therapeutic agents include, e.g., an inhibitor, agonist, antagonist, ligand, modulator, stimulator, blocker, activator or suppressor of a target (e.g., polypeptide or polynucleotide), such as: 2'-5'-oligoadenylate synthetase (OAS1; NCBI Gene ID: 4938); 5'-3' exoribonuclease 1 (XRN1; NCBI Gene ID: 54464); 5'-nucleotidase ecto (NT5E, CD73; NCBI Gene ID: 4907); ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1, BCR-ABL, c-ABL, v-ABL; NCBI Gene ID: 25); absent in melanoma 2 (AIM2; NCBI Gene ID: 9447); acetyl-CoA acyl
• a target e.g., polypeptide
• the one or more additional therapeutic agents include, e.g., an agent targeting 5'-nucleotidase ecto (NT5E or CD73; NCBI Gene ID: 4907); adenosine A2A receptor (ADORA2A; NCBI Gene ID: 135); adenosine A2B receptor (ADORA2B; NCBI Gene ID: 136); C-C motif chemokine receptor 8 (CCR8, CDw198; NCBI Gene ID: 1237); cytokine inducible SH2 containing protein (CISH; NCBI Gene ID: 1154); diacylglycerol kinase alpha (DGKA, DAGK, DAGK1 or DGK-alpha; NCBI Gene ID: 1606); fms like tyrosine kinase 3 (FLT3, CD135; NCBI Gene ID: 2322); integrin associated protein (IAP, CD47; NCBI Gene ID: 961); interleukin e e 3 (F
• a compound provided herein is administered with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and/or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors.
• Blockade or inhibition of inhibitory immune checkpoints can positively regulate T- cell or NK cell activation and prevent immune escape of cancer cells within the tumor microenvironment.
• Activation or stimulation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in cancer therapeutics.
• the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu, et al., J Exp Clin Cancer Res. (2016) 37:110).
• the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis, et al., Semin Immunol. (2017) 31:64–75 and Chiossone, et al., Nat Rev Immunol. (2016) 18(11):671-688).
• Inhibition of regulatory T-cells (Treg) or Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects (e.g., reviewed in Plitas and Rudensky, Annu. Rev. Cancer Biol. (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol. (2019) 49:1140-1146).
• immune checkpoint proteins or receptors examples include CD27 (NCBI Gene ID: 939), CD70 (NCBI Gene ID: 970); CD40 (NCBI Gene ID: 958), CD40LG (NCBI Gene ID: 959); CD47 (NCBI Gene ID: 961), SIRPA (NCBI Gene ID: 140885); CD48 (SLAMF2; NCBI Gene ID: 962), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H; NCBI Gene ID: 126259), CD84 (LY9B, SLAMF5; NCBI Gene ID: 8832), CD96 (NCBI Gene ID: 10225), CD160 (NCBI Gene ID: 11126), MS4A1 (CD20; NCBI Gene ID: 931), CD244 (SLAMF4; NCBI Gene ID: 51744); CD276 (B7H3; NCBI Gene ID: 80381); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory
• a compound provided herein is administered with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors.
• T-cell inhibitory immune checkpoint proteins or receptors include CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD11
• the compound provided herein is administered with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors.
• T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7- 1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155).
• the compound provided herein is administered with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors.
• NK-cell inhibitory immune checkpoint proteins or receptors include killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor D1 (KLRD1, CD94), killer cell lectin like receptor G1 (KLRG1; CLEC15A, MAFA, 2F1); sialic acid binding Ig like lectin 7 (SIGLEC7); and sialic acid binding I
• the compound provided herein is administered with one or more agonist or activators of one or more NK-cell stimulatory immune checkpoint proteins or receptors.
• NK-cell stimulatory immune checkpoint proteins or receptors include CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis, et al., Semin Immunol. (2017) 31:64–75; Fang, et al., Semin Immunol. (2017) 31:37-54; and Chiossone, et al., Nat Rev Immunol.
• the one or more immune checkpoint inhibitors comprises a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT.
• the one or more immune checkpoint inhibitors comprises a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1), CTLA4, or TIGIT.
• the one or more immune checkpoint inhibitors comprises a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of LAG3.
• inhibitors of CTLA4 include ipilimumab, tremelimumab, BMS-986218, AGEN1181, zalifrelimab (AGEN1884), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002 (ipilimumab biosimilar), BCD-145, APL-509, JS-007, BA- 3071, ONC-392, AGEN-2041, HBM-4003, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI- 5D3H5, BPI-002, as well as multi-specific inhibitors FPT-155 (CTLA4/PD-L1/CD28), PF- 06936308 (PD-1/ CTLA4), MGD-019 (PD-1/CTLA4), KN-046 (PD-1/CTLA4), MEDI-5752 (CTLA4/PD-1), XmAb-20717
• inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be co-administered include pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP- 514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, cosibelimab (CK-301), sasanlimab (PF-06801591), tislelizumab (BGB-A317), GLS-010 (WBP-3055), AK-103 (HX- 008), AK-105, CS-1003, HLX-10, retifanlimab (MGA-012), BI-754091, balstilimab (AGEN- 2034), AMG-404, toripalimab (JS-001), cetrelimab (JNJ-6
• the PD-L1 inhibitor is a small molecule inhibitor, such as CA-170, GS-4224, GS-4416 and lazertinib (GNS-1480; PD-L1/EGFR).
• Examples of inhibitors of TIGIT that can be co-administered include tiragolumab (RG-6058), vibostolimab, domvanalimab, domvanalimab (AB154), AB308, BMS-986207, AGEN-1307, COM-902, or etigilimab.
• Examples of inhibitors of LAG3 that can be co-administered include leramilimab (LAG525).
• Treg activity or Treg depletion can alleviate their suppression of antitumor immune responses and have anticancer effects. See, e.g., Plitas and Rudensky, Annu. Rev. Cancer Biol. (2020) 4:459-77; Tanaka and Sakaguchi, Eur. J. Immunol. (2019) 49:1140-1146.
• an compound provided herein is administered with one or more inhibitors of Treg activity or a Treg depleting agent. Treg inhibition or depletion can augment the effect of immune checkpoint inhibitors in cancer therapeutics.
• an compound provided herein is administered with one or more Treg inhibitors.
• the Treg inhibitor can suppress the migration of Tregs into the tumor microenvironment. In some embodiments Treg inhibitor can reduce the immunosuppressive function of Tregs. In some embodiments, the Treg inhibitor can modulate the cellular phenotype and induce production of proinflammatory cytokines.
• Exemplary Treg inhibitors include without limitation, CCR4 (NCBI Gene ID: 1233) antagonists and degraders of Ikaros zinc-finger proteins (e.g., Ikaros (IKZF1; NCBI Gene ID: 10320), Helios (IKZF2; NCBI Gene ID: 22807), Aiolos (IKZF3; NCBI Gene ID: 22806), and Eos (IKZF4; NCBI Gene ID: 64375).
• Helios degraders examples include without limitation I-57 (Novartis) and compounds disclosed in WO2019038717, WO2020012334, WO20200117759, and WO2021101919.
• an compound provided herein is administered with one or more Treg depleting agents.
• the Treg depleting agent is an antibody.
• the Treg depleting antibody has antibody-dependent cytotoxic (ADCC) activity.
• the Treg depleting antibody is Fc-engineered to possess an enhanced ADCC activity.
• the Treg depleting antibody is an antibody-drug conjugate (ADC).
• Illustrative targets for Treg depleting agents include without limitation CD25 (IL2RA; NCBI Gene ID: 3559), CTLA4 (CD152; NCBI Gene ID: 1493); GITR (TNFRSF18; NCBI Gene ID: 8784); 4-1BB (CD137; NCBI Gene ID: 3604), OX-40 (CD134; NCBI Gene ID: 7293), LAG3 (CD223; NCBI Gene ID: 3902), TIGIT (NCBI Gene ID: 201633), CCR4 (NCBI Gene ID: 1233), and CCR8 (NCBI Gene ID: 1237).
• CD25 IL2RA
• CTLA4 CD152; NCBI Gene ID: 1493
• GITR TNFRSF18; NCBI Gene ID: 8784
• 4-1BB CD137; NCBI Gene ID: 3604
• OX-40 CD134; NCBI Gene ID: 7293
• LAG3 CD223; NCBI Gene ID: 3902
• TIGIT NCBI Gene ID: 201633
• CCR4 NCBI Gene
• the Treg inhibitor or Treg depleting agent that can be co- administered comprises an antibody or antigen-binding fragment thereof that selectively binds to a cell surface receptor selected from the group consisting of C-C motif chemokine receptor 4 (CCR4), C-C motif chemokine receptor 7 (CCR7), C-C motif chemokine receptor 8 (CCR8), C- X-C motif chemokine receptor 4 (CXCR4; CD184), TNFRSF4 (OX40), TNFRSF18 (GITR, CD357), TNFRSF9 (4-1BB, CD137), cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152), programmed cell death 1 (PDCD1, PD-1), Sialyl Lewis x (CD15s), CD27, ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; CD39), protein tyrosine phosphatase receptor type C (PTPRC; CD45), neural cell adhe
• CCR4 C-
• Treg depleting anti-CCR8 antibodies that can be administered include without limitation JTX-1811 (GS-1811) (Jounce Therapeutics, Gilead Sciences), BMS-986340 (Bristol Meyers Squibb), S-531011 (Shionogi), FPA157 (Five Prime Therapeutics), SRF-114 (Surface Oncology), HBM1022 (Harbor BioMed), IO-1 (Oncurious), and antibodies disclosed in WO2021163064, WO2020138489, and WO2021152186.
• Examples of Treg depleting anti-CCR4 antibodies that can be administered include mogamulizumab.
• Inhibiting, depleting, or reprogramming of non-stimulatory myeloid cells in the tumor microenvironment can enhance anti-cancer immune responses (see, e.g., Binnewies et al., Nat. Med. (2016) 24(5): 541-550; WO2016049641).
• Illustrative targets for depleting or reprogramming non-stimmulatory myeloid cells include triggering receptors expressed on myeloid cells, TREM-1 (CD354, NCBI Gene ID: 54210) and TREM-2 (NCBI Gene ID: 54209).
• an compound provided herein is administered with one or more myeloid cell depleting or reprogramming agents, such as an anti-TREM-1 antibody (e.g.
• the compound provided herein is administered with agents targeting a cluster of differentiation (CD) marker.
• CD cluster of differentiation
• CD marker targeting agents that can be co-administered include without limitation A6, AD-IL24, neratinib, tucatinib (ONT 380), mobocertinib (TAK-788), tesevatinib, trastuzumab (HERCEPTIN®), trastuzumab biosimimar (HLX-02), margetuximab, BAT-8001, pertuzumab (Perjeta), pegfilgrastim, RG6264, zanidatamab (ZW25), cavatak, AIC-100, tagraxofusp (SL-401), HLA-A2402/HLA-A0201 restricted epitope peptide vaccine, dasatinib, imatinib, nilotinib, sorafenib, lenvatinib mesylate, ofranergene obadenovec, cabozantinib malate, AL-8326, ZLJ-
• the CD marker targeting agent that can be co-administered include small molecule inhibitors, such as PBF-1662, BLZ-945, pemigatinib (INCB-054828), rogaratinib (BAY-1163877), AZD4547, roblitinib (FGF-401), quizartinib dihydrochloride, SX-682, AZD- 5069, PLX-9486, avapritinib (BLU-285), ripretinib (DCC-2618), imatinib mesylate, JSP-191, BLU-263, CD117-ADC, AZD3229, telatinib, vorolanib, GO-203-2C, AB-680, PSB-
• the CD marker targeting agent that can be co-administered include small molecule agonists, such as interleukin 2 receptor subunit gamma, eltrombopag, rintatolimod, poly-ICLC (NSC-301463), Riboxxon, Apoxxim, RIBOXXIM®, MCT-465, MCT- 475, G100, PEPA-10, eftozanermin alfa (ABBV-621), E-6887, motolimod, resiquimod, selgantolimod (GS-9688), VTX-1463, NKTR-262, AST-008, CMP-001, cobitolimod, tilsotolimod, litenimod, MGN-1601, BB-006, IMO-8400, IMO-9200, agatolimod, DIMS-9054, DV-1079, lefitolimod (MGN-1703), CYT-003, and PUL-042.
• small molecule agonists such as
• the CD marker targeting agent that can be co-administered include antibodies, such as tafasitamab (MOR208; MorphoSys AG), Inebilizumab (MEDI-551), obinutuzumab, IGN-002, rituximab biosimilar (PF-05280586), varlilumab (CDX-1127), AFM-13 (CD16/CD30), AMG330, otlertuzumab (TRU-016), isatuximab, felzartamab (MOR-202), TAK- 079, TAK573, daratumumab (DARZALEX®), TTX-030, selicrelumab (RG7876), APX-005M, ABBV-428, ABBV-927, mitazalimab (JNJ-64457107), lenziluma, alemtuzuma, emactuzumab, AMG-820, FPA-
• antibodies such as t
• the CD marker targeting agent that can be co-administered include cell therapies, such as CD19-ARTEMIS, TBI-1501, CTL-119 huCART-19 T cells, l iso-cel, lisocabtagene maraleucel (JCAR-017), axicabtagene ciloleucel (KTE-C19, Yescarta®), axicabtagene ciloleucel (KTE-X19), US7741465, US6319494, UCART-19, tabelecleucel (EBV- CTL), T tisagenlecleucel-T (CTL019), CD19CAR-CD28-CD3zeta-EGFRt-expressing T cells, CD19/4-1BBL armored CAR T cell therapy, C-CAR-011, CIK-CAR.CD19, CD19CAR-28-zeta T cells, PCAR-019, MatchCART, DSCAR-01, IM19 CAR-T,
• cell therapies such as CD
• CD47 Cluster of Differentiation 47
• the compound provided herein is administered with an inhibitor of CD47 (IAP, MER6, OA3; NCBI Gene ID: 961).
• CD47 inhibitors include anti-CD47 mAbs (Vx-1004), anti-human CD47 mAbs (CNTO-7108), CC-90002, CC-90002-ST-001, humanized anti-CD47 antibody or a CD47-blocking agent, NI-1701, NI-1801, RCT-1938, ALX148, SG-404, SRF-231, and TTI-621.
• Additional exemplary anti-CD47 antibodies include CC-90002, magrolimab (Hu5F9-G4), AO-176 (Vx-1004), letaplimab (IBI-188) (letaplimab), lemzoparlimab (TJC-4), SHR-1603, HLX-24, LQ-001, IMC-002, ZL-1201, IMM-01, B6H12, GenSci-059, TAY-018, PT-240, 1F8-GMCSF, SY-102, KD-015, ALX-148, AK-117, TTI-621, TTI-622, or compounds disclosed in WO199727873, WO199940940, WO2002092784, WO2005044857, WO2009046541, WO2010070047, WO2011143624, WO2012170250, WO2013109752, WO2013119714, WO2014087248, WO2015191861, WO2016022971, WO20160230
• the CD47 inhibitor is RRx-001, DSP-107, VT-1021, IMM-02, SGN-CD47M, or SIRPa ⁇ Fc ⁇ CD40L (SL-172154). In some embodiments the CD47 inhibitor is magrolimab.
• the CD47 inhibitor is a bispecific antibodies targeting CD47, such as IBI-322 (CD47/PD-L1), IMM-0306 (CD47/CD20), TJ-L1C4 (CD47/PD-L1), HX-009 (CD47/PD-1), PMC-122 (CD47/PD-L1), PT-217, (CD47/DLL3), IMM-26011 (CD47/FLT3), IMM-0207 (CD47/VEGF), IMM-2902 (CD47/HER2), BH29xx (CD47/PD-L1), IMM-03 (CD47/CD20), IMM-2502 (CD47/PD-L1), HMBD-004B (CD47/BCMA), HMBD-004A (CD47/CD33), TG-1801 (NI-1701), or NI-1801.
• CD47 such as IBI-322 (CD47/PD-L1), IMM-0306 (CD47/CD20), TJ-L1C4 (CD47/PD
• SIRPa Targeting Agents [0286] In some embodiments the compound provided herein is administered with a SIRPa targeting agent (NCBI Gene ID: 140885; UniProt P78324).
• SIRPa targeting agents include SIRPa inhibitors, such as AL-008, RRx-001, and CTX-5861, and anti-SIRPa antibodies, such as FSI-189 (GS-0189), ES-004, BI-765063, ADU1805, CC-95251, Q-1801 (SIRPa/PD-L1).
• SIRP ⁇ -targeting agents of use are described, for example, in WO200140307, WO2002092784, WO2007133811, WO2009046541, WO2010083253, WO2011076781, WO2013056352, WO2015138600, WO2016179399, WO2016205042, WO2017178653, WO2018026600, WO2018057669, WO2018107058, WO2018190719, WO2018210793, WO2019023347, WO2019042470, WO2019175218, WO2019183266, WO2020013170 and WO2020068752.
• the compound provided herein is administered with a FLT3R agonist. In some embodiments, the compound provided herein is administered with a FLT3 ligand. In some embodiments, the compound provided herein is administered with a FLT3L-Fc fusion protein, e.g., as described in WO2020263830. In some embodiments the compound provided herein is administered with GS-3583 or CDX-301. In some embodiments the compound provided herein is administered with GS-3583.
• TNF Receptor Superfamily Member Agonists or Activators
• the compound provided herein is administered with an agonist of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI Gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI Gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR
• TNFRSF10A CD261,
• Example anti-TNFRSF4 (OX40) antibodies that can be co-administered include MEDI6469, MEDI6383, tavolixizumab (MEDI0562), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.
• Example anti-TNFRSF5 (CD40) antibodies that can be co-administered include RG7876, SEA-CD40, APX-005M, and ABBV-428.
• the anti-TNFRSF7 (CD27) antibody varlilumab (CDX-1127) is co- administered.
• Example anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include urelumab, utomilumab (PF-05082566), AGEN-2373, and ADG-106.
• the anti-TNFRSF17 (BCMA) antibody GSK-2857916 is co-administered.
• Example anti-TNFRSF18 (GITR) antibodies that can be co-administered include MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628.
• an antibody, or fragment thereof, co-targeting TNFRSF4 (OX40) and TNFRSF18 (GITR) is co-administered.
• Such antibodies are described, e.g., in WO2017096179 and WO2018089628.
• Bi-specific antibodies targeting TNFRSF family members include PRS-343 (CD-137/HER2), AFM26 (BCMA/CD16A), AFM-13 (CD16/CD30), odronextamab (REGN-1979; CD20/CD3), AMG-420 (BCMA/CD3), INHIBRX-105 (4- 1BB/PDL1), FAP-4-IBBL (4-1BB/FAP), plamotamab (XmAb-13676; CD3/CD20), RG-7828 (CD20/CD3), CC-93269 (CD3/BCMA), REGN-5458 (CD3/BCMA), and IMM-0306 (CD47/CD20).
• PRS-343 CD-137/HER2
• AFM26 BCMA/CD16A
• AFM-13 CD16/CD30
• odronextamab REGN-1979; CD20/CD3
• AMG-420 BCMA/CD3
• INHIBRX-105 (4- 1BB/PDL1)
• compound provided herein is administered with a bi-specific T-cell engager (e.g., not having an Fc) or an anti-CD3 bi-specific antibody (e.g., having an Fc).
• a bi-specific T-cell engager e.g., not having an Fc
• an anti-CD3 bi-specific antibody e.g., having an Fc
• Illustrative anti-CD3 bi-specific antibodies or BiTEs that can be co-administered include duvortuxizumab (JNJ-64052781; CD19/CD3), AMG-211 (CEA/CD3), AMG-160 (PSMA/CD3), RG7802 (CEA/CD3), ERY-974 (CD3/GPC3), PF-06671008 (Cadherins/CD3), APVO436 (CD123/CD3), flotetuzumab (CD123/CD3), odronextamab (REGN-1979; CD20/CD3), MCLA- 117 (CD3/CLEC12A), JNJ-0819 (heme/CD3), JNJ-7564 (CD3/heme), AMG-757 (DLL3-CD3), AMG-330 (CD33/CD3), AMG-420 (BCMA/CD3), AMG-427 (FLT3/CD3), AMG-562 (CD19/CD3), A
• the anti-CD3 binding bi- specific molecules may or may not have an Fc.
• Illustrative bi-specific T-cell engagers that can be co-administered target CD3 and a tumor-associated antigen as described herein, including, e.g., CD19 (e.g., blinatumomab); CD33 (e.g., AMG330); CEA (e.g., MEDI-565); receptor tyrosine kinase-like orphan receptor 1 (ROR1) (Gohil, et al., Oncoimmunology. (2017) May 17;6(7):e1326437); PD-L1 (Horn, et al., Oncotarget.
• CD19 e.g., blinatumomab
• CD33 e.g., AMG330
• CEA e.g., MEDI-565
• ROR1 receptor tyrosine kinase-like orphan receptor 1
• NK-cell Engagers Bi-and Tri-Specific Natural Killer (NK)-Cell Engagers
• BiKE bi-specific NK-cell engager
• TriKE tri-specific NK-cell engager
• NK cell activating receptor e.g., CD16A, C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor Fc ⁇ R (which mediates antibody-dependent cell cytotoxicity),
• Illustrative anti-CD16 bi-specific antibodies, BiKEs or TriKEs that can be co-administered include AFM26 (BCMA/CD16A) and AFM-13 (CD16/CD30).
• the anti-CD16 binding bi-specific molecules may or may not have an Fc.
• MCL1 apoptosis regulator BCL2 family member (MCL1) Inhibitors
• the compound provided herein is administered with an inhibitor of MCL1 apoptosis regulator, BCL2 family member (MCL1, TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1/EAT; NCBI Gene ID: 4170).
• MCL1 inhibitors include tapotoclax (AMG-176), AMG-397, S-64315, AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037, PRT-1419, GS-9716, and those described in WO2018183418, WO2016033486, and WO2017147410.
• SHP2 Inhibitors [0299] In some embodiments compound provided herein is administered with an inhibitor of protein tyrosine phosphatase non-receptor type 11 (PTPN11; BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2; NCBI Gene ID: 5781).
• PTPN11 protein tyrosine phosphatase non-receptor type 11
• SHP2 inhibitors examples include TNO155 (SHP-099), RMC-4550, JAB-3068, RMC-4630, and those described in WO2018172984 and WO2017211303.
• HPK1 Hematopoietic Progenitor Kinase 1
• HPK1 mitogen-activated protein kinase kinase kinase kinase 1
• Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors include without limitation, those described in WO2020092621, WO2018183956, WO2018183964, WO2018167147, WO2018049152, WO2020092528, WO2016205942, WO2016090300, WO2018049214, WO2018049200, WO2018049191, WO2018102366, WO2018049152, and WO2016090300.
• Apoptosis Signal-Regulating Kinase (ASK) Inhibitors [0301]
• the compound provided herein is administered with an ASK inhibitor, e.g., mitogen-activated protein kinase kinase kinase 5 (MAP3K5; ASK1, MAPKKK5, MEKK5; NCBI Gene ID: 4217).
• ASK inhibitors include those described in WO2011008709 (Gilead Sciences) and WO 2013112741 (Gilead Sciences).
• Bruton Tyrosine Kinase (BTK) Inhibitors [0302] In some embodiments the compound provided herein is administered with an inhibitor of Bruton tyrosine kinase (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI Gene ID: 695).
• BTK Bruton Tyrosine Kinase
• BTK inhibitors include (S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin- 3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), zanubrutinib (BGB- 3111), CB988, HM71224, ibrutinib, M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, spebrutinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS- 12, PCI-32765, and TAS-5315.
• Cyclin-dependent Kinase (CDK) Inhibitors [0303] In some embodiments the compound provided herein is administered with an inhibitor of cyclin dependent kinase 1 (CDK1, CDC2; CDC28A; P34CDC2; NCBI Gene ID: 983); cyclin dependent kinase 2 (CDK2, CDKN2; p33(CDK2); NCBI Gene ID: 1017); cyclin dependent kinase 3 (CDK3, ; NCBI Gene ID: 1018); cyclin dependent kinase 4 (CDK4, CMM3; PSK-J3; NCBI Gene ID: 1019); cyclin dependent kinase 6 (CDK6, MCPH12; PLSTIRE; NCBI Gene ID: 1021); cyclin dependent kinase 7 (CDK7, CAK; CAK1; HCAK; MO15; STK1; CDKN7; p39MO15; NCBI Gene ID: 1022), or cyclin dependent kinas
• Inhibitors of CDK 1, 2, 3, 4, 6, 7 and/or 9 include abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519, dinaciclib, ibrance, FLX-925, LEE001, palbociclib, samuraciclib, ribociclib, rigosertib, selinexor, UCN-01, SY1365, CT-7001, SY-1365, G1T38, milciclib, trilaciclib, simurosertib hydrate (TAK931), and TG-02.
• DDR Discoidin Domain Receptor
• the compound provided herein is combined with an inhibitor of discoidin domain receptor tyrosine kinase 1 (DDR1, CAK, CD167, DDR, EDDR1, HGK2, MCK10, NEP, NTRK4, PTK3, PTK3A, RTK6, TRKE; NCBI Gene ID: 780); and/or discoidin domain receptor tyrosine kinase 2 (DDR2, MIG20a, NTRKR3, TKT, TYRO10, WRCN; NCBI Gene ID: 4921).
• DDR inhibitors include dasatinib and those disclosed in WO2014/047624 (Gilead Sciences), US 2009-0142345 (Takeda Pharmaceutical), US 2011- 0287011 (Oncomed Pharmaceuticals), WO 2013/027802 (Chugai Pharmaceutical), and WO2013/034933 (Imperial Innovations).
• Targeted E3 Ligase Ligand Conjugates [0305] In some embodiments the compound provided herein is administered with a targeted E3 ligase ligand conjugate.
• Such conjugates have a target protein binding moiety and an E3 ligase binding moiety (e.g., an inhibitor of apoptosis protein (IAP) (e.g., XIAP, c-IAP1, c-IAP2, NIL- IAP, Bruce, and surviving) E3 ubiquitin ligase binding moiety, Von Hippel-Lindau E3 ubiquitin ligase (VHL) binding moiety, a cereblon E3 ubiquitin ligase binding moiety, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase binding moiety), and can be used to promote or increase the degradation of targeted proteins, e.g., via the ubiquitin pathway.
• IAP apoptosis protein
• VHL Von Hippel-Lindau E3 ubiquitin ligase
• MDM2 mouse double minute 2 homolog
• the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein described herein, and an E3 ligase ligand or binding moiety.
• the targeted E3 ligase ligand conjugates comprise a targeting or binding moiety that targets or binds a protein selected from Cbl proto-oncogene B (CBLB; Cbl-b, Nbla00127, RNF56; NCBI Gene ID: 868) and hypoxia inducible factor 1 subunit alpha (HIF1A; NCBI Gene ID: 3091).
• the targeted E3 ligase ligand conjugates comprise a kinase inhibitor (e.g., a small molecule kinase inhibitor, e.g., of BTK and an E3 ligase ligand or binding moiety. See, e.g., WO2018098280.
• a kinase inhibitor e.g., a small molecule kinase inhibitor, e.g., of BTK and an E3 ligase ligand or binding moiety. See, e.g., WO2018098280.
• the targeted E3 ligase ligand conjugates comprise a binding moiety targeting or binding to Interleukin-1 (IL-1) Receptor-Associated Kinase-4 (IRAK- 4); Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF), c-Met/p38, or a BRD protein; and an E3 ligase ligand or binding moiety.
• IL-1 Interleukin-1
• IRAK- 4 Rapidly Accelerated Fibrosarcoma
• RAF such as c-RAF, A-RAF and/or B-RAF
• c-Met/p38 c-Met/p38
• BRD protein BRD protein
• E3 ligase ligand or binding moiety See, e.g., WO2019099926, WO2018226542, WO2018119448, WO2018223909, WO2019079701.
• HDAC Histone Deacetylase
• the compound provided herein is administered with an inhibitor of a histone deacetylase, e.g., histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734).
• HDAC inhibitors include abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat.
• Indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors [0307] In some embodiments the compound provided herein is administered with an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620).
• IDO1 inhibitors examples include BLV-0801, epacadostat, linrodostat (F-001287, BMS-986205), GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, and shIDO-ST, EOS-200271, KHK-2455, and LY-3381916.
• Janus Kinase (JAK) Inhibitors [0308]
• the compound provided herein is administered with an inhibitor of Janus kinase 1 (JAK1, JAK1A, JAK1B, JTK3; NCBI Gene ID: 3716); Janus kinase 2 (JAK2, JTK10, THCYT3; NCBI Gene ID: 3717); and/or Janus kinase 3 (JAK3, JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK; NCBI Gene ID: 3718).
• JAK inhibitors include AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib (CYT0387), ilginatinib maleate (NS-018), pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly tasocitinib), INCB052793, and XL019.
• LOXL Lysyl Oxidase-Like Protein
• the compound provided herein is administered with an inhibitor of a LOXL protein, e.g., LOXL1 (NCBI Gene ID: 4016), LOXL2 (NCBI Gene ID: 4017), LOXL3 (NCBI Gene ID: 84695), LOXL4 (NCBI Gene ID: 84171), and/or LOX (NCBI Gene ID: 4015).
• LOXL2 inhibitors include the antibodies described in WO 2009017833 (Arresto Biosciences), WO 2009035791 (Arresto Biosciences), and WO 2011097513 (Gilead Biologics).
• MMP Matrix Metalloprotease
• the compound provided herein is administered with an inhibitor of a matrix metallopeptidase (MMP), e.g., an inhibitor of MMP1 (NCBI Gene ID: 4312), MMP2 (NCBI Gene ID: 4313), MMP3 (NCBI Gene ID: 4314), MMP7 (NCBI Gene ID: 4316), MMP8 (NCBI Gene ID: 4317), MMP9 (NCBI Gene ID: 4318); MMP10 (NCBI Gene ID: 4319); MMP11 (NCBI Gene ID: 4320); MMP12 (NCBI Gene ID: 4321), MMP13 (NCBI Gene ID: 4322), MMP14 (NCBI Gene ID: 4323), MMP15 (NCBI Gene ID: 4324), MMP16 (NCBI Gene ID: 4325), MMP17 (NCBI Gene ID: 4326), MMP19 (NCBI Gene ID: 4327), MMP20 (NCBI Gene ID: 9313), MMP21 (NCBI Gene ID: 4312), MMP2 (
• MMP9 inhibitors include marimastat (BB-2516), cipemastat (Ro 32-3555), GS-5745 (andecaliximab), and those described in WO 2012027721 (Gilead Biologics).
• RAS and RAS Pathway Inhibitors [0311] In some embodiments the compound provided herein is administered with an inhibitor of KRAS proto-oncogene, GTPase (KRAS; a.k.a., NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2; NCBI Gene ID: 3845); NRAS proto-oncogene, GTPase (NRAS; a.k.a., NS6; CMNS; NCMS;
• the Ras inhibitors can inhibit Ras at either the polynucleotide (e.g., transcriptional inhibitor) or polypeptide (e.g., GTPase enzyme inhibitor) level.
• the inhibitors target one or more proteins in the Ras pathway, e.g., inhibit one or more of EGFR, Ras, Raf (A-Raf, B-Raf, C-Raf), MEK (MEK1, MEK2), ERK, PI3K, AKT and mTOR.
• K-Ras inhibitors that can be co- administered include sotorasib (AMG-510), COTI-219, ARS-3248, WDB-178, BI-3406, BI- 1701963, SML-8-73-1 (G12C), adagrasib (MRTX-849), ARS-1620 (G12C), SML-8-73-1 (G12C), Compound 3144 (G12D), Kobe0065/2602 (Ras GTP), RT11, MRTX-849 (G12C) and K-Ras(G12D)-selective inhibitory peptides, including KRpep-2and KRpep-2d .
• Illustrative KRAS mRNA inhibitors include anti-KRAS U1 adaptor, AZD-4785, siG12D-LODERTM, and siG12D exosomes.
• Illustrative MEK inhibitors that can be co-administered include binimetinib, cobimetinib, PD-0325901, pimasertib, RG-7304, selumetinib, trametinib, and those described below and herein.
• Illustrative Raf dimer inhibitors that can be co-administered include BGB-283, HM-95573, LXH-254, LY-3009120, RG7304 and TAK-580.
• Illustrative ERK inhibitors that can be co-administered include LTT-462, LY-3214996, MK-8353, ravoxertinib and ulixertinib.
• Illustrative Ras GTPase inhibitors that can be co-administered include rigosertib.
• Illustrative PI3K inhibitors that can be co-administered include idelalisib (Zydelig®), alpelisib, buparlisib, pictilisib, inavolisib (RG6114), ASN-003.
• Illustrative AKT inhibitors that can be co-administered include capivasertib and GSK2141795.
• Illustrative PI3K/mTOR inhibitors that can be co- administered include dactolisib, omipalisib, voxtalisib.
• gedatolisib GSK2141795, GSK- 2126458, inavolisib (RG6114), sapanisertib, ME-344, sirolimus (oral nano-amorphous formulation, cancer), racemetyrosine (TYME-88 (mTOR/cytochrome P4503A4)), temsirolimus (TORISEL®, CCI-779), CC-115, onatasertib (CC-223), SF-1126, and PQR-309 (bimiralisib).
• Ras-driven cancers having CDKN2A mutations can be inhibited by co-administration of the MEK inhibitor selumetinib and the CDK4/6 inhibitor palbociclib.
• MEK inhibitor selumetinib and CDK4/6 inhibitor palbociclib See, e.g., Zhou, et al., Cancer Lett. 2017 Nov 1;408:130-137.
• K-RAS and mutant N-RAS can be reduced by the irreversible ERBB1/2/4 inhibitor neratinib. See, e.g., Booth, et al., Cancer Biol Ther. 2018 Feb 1;19(2):132-137.
• Mitogen-activated Protein Kinase (MEK) Inhibitors [0312] In some embodiments the compound provided herein is administered with an inhibitor of mitogen-activated protein kinase kinase 7 (MAP2K7, JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7, SAPKK-4, SAPKK4; NCBI Gene ID: 5609).
• mitogen-activated protein kinase kinase 7 MAP2K7, JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7, SAPKK-4, SAPKK4; NCBI Gene ID: 5609.
• MEK inhibitors include antroquinonol, binimetinib, cobimetinib (GDC-0973, XL-518), MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212), uprosertib + trametinib, PD-0325901, pimasertib, LTT462, AS703988, CC-90003, and refametinib.
• Phosphatidylinositol 3-kinase (PI3K) Inhibitors [0313] In some embodiments compounds provided herein is administered with an inhibitor of a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, e.g., phosphatidylinositol-4,5- bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-alpha, p110-alpha; NCBI Gene ID: 5290); phosphatidylinositol- 4,5-bisphosphate 3-kinase catalytic subunit beta (PIK3CB, P110BETA, PI3K, PI3KBETA, PIK3C1; NCBI Gene ID: 5291); phosphatidylinositol-4,5-bisphosphate 3-kinase cata
• the PI3K inhibitor is a pan-PI3K inhibitor.
• PI3K inhibitors include ACP-319, AEZA-129, AMG-319, AS252424, AZD8186, BAY 10824391, BEZ235, buparlisib (BKM120), BYL719 (alpelisib), CH5132799, copanlisib (BAY 80-6946), duvelisib, GDC-0032, GDC-0077, GDC- 0941, GDC-0980, GSK2636771, GSK2269557, idelalisib (Zydelig®), INCB50465, IPI-145, IPI- 443, IPI-549, KAR4141, LY294002, LY3023414, MLN1117, OXY111A, PA799, PX-866, RG7604, rigosertib, RP5090, RP6530, SRX3177, t
• Spleen Tyrosine Kinase (SYK) Inhibitors [0314] In some embodiments the compound provided herein is administered with an inhibitor of spleen associated tyrosine kinase (SYK, p72-Syk, NCBI Gene ID: 6850).
• SYK inhibitors include 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib (R788), HMPL-523, NVP-QAB 205 AA, R112, R343, tamatinib (R406), gusacitinib (ASN-002), and those described in US8450321 (Gilead Connecticut) and US20150175616.
• TLR Toll-Like Receptor Agonists
• compound provided herein is administered with an agonist of a toll- like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and/or TLR10 (NCBI Gene ID: 81793).
• TLR1 NCBI Gene ID: 7096
• TLR2 NCBI Gene ID: 7097
• TLR3 NCBI Gene ID: 7098
• TLR4 NCBI Gene ID: 7099
• TLR5 NCBI Gene ID: 7100
• TLR6 NCBI Gene ID: 10333
• TLR7 NCBI Gene
• Example TLR7 agonists that can be co-administered include DS-0509, GS-9620 (vesatolimod), vesatolimod analogs, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO- 4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG- 7863, RG-7795, BDB-001, DSP-0509, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014056953 (Janssen), WO2014076221 (Janssen), WO2014128189 (Janssen), US
• TLR7/TLR8 agonist that can be co-administered is NKTR-262.
• Example TLR8 agonists that can be co-administered include E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M-052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014/056953 (Janssen), WO2014/076221 (Janssen), WO2014/128189 (Janssen), US20140350031 (Janssen), WO2014/023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118
• Example TLR9 agonists that can be co-administered include AST-008, CMP-001, IMO-2055, IMO-2125, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod (MGN-1703), CYT-003, CYT-003- QbG10 and PUL-042.
• TLR3 agonist examples include rintatolimod, poly-ICLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1.
• Tyrosine-kinase Inhibitors TKIs
• TKIs may target epidermal growth factor receptors (EGFRs) and receptors for fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF).
• EGFRs epidermal growth factor receptors
• FGF fibroblast growth factor
• PDGF platelet-derived growth factor
• VEGF vascular endothelial growth factor
• TKIs include without limitation afatinib, ARQ- 087 (derazantinib), asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, gilteritinib (ASP-2215), FP-1039, HM61713, icotinib, imatinib, KX2-391 (Src), lapatinib, lestaurtinib, lenvatinib, midostaurin, nintedanib, ODM-203, osimertinib (AZD-9291), ponatinib, poziotinib, quizartinib, radotinib,
• Exemplary EGFR targeting agents include neratinib, tucatinib (ONT-380), tesevatinib, mobocertinib (TAK-788), DZD-9008, varlitinib, abivertinib (ACEA-0010), EGF816 (nazartinib), olmutinib (BI-1482694), osimertinib (AZD-9291), AMG-596 (EGFRvIII/CD3), lifirafenib (BGB-283), vectibix, lazertinib (LECLAZA®), and compounds disclosed in Booth, et al., Cancer Biol Ther.
• Antibodies targeting EGFR include without limitation modotuximab, cetuximab sarotalocan (RM-1929), seribantumab, necitumumab, depatuxizumab mafodotin (ABT-414), tomuzotuximab, depatuxizumab (ABT-806), and cetuximab.
• Chemotherapeutic agents [0317] In some embodiments the compound provided herein is administered with a chemotherapeutic agent or anti-neoplastic agent.
• chemotherapeutic agent or “chemotherapeutic” (or “chemotherapy” in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (e.g., non-peptidic) chemical compound useful in the treatment of cancer.
• chemotherapeutic agents include but not limited to: alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodepa, carboquone, meturedepa, and uredepa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimemylolomelamine; acetogenins, e.g., bullatacin and bullatacinone; a camptothecin, including synthetic analog topotecan; bryostatin, callystatin; CC- 1065, including its adozelesin, carzelesin, and bizelesin synthetic analogs; cryptophycins, particularly cryptophycin 1 and cryptophycin 8;dolastat
• Anti-hormonal Agents [0319] Also included in the definition of “chemotherapeutic agent” are anti-hormonal agents such as anti-estrogens and selective estrogen receptor modulators (SERMs), inhibitors of the enzyme aromatase, anti-androgens, and pharmaceutically acceptable salts, acids or derivatives of any of the above that act to regulate or inhibit hormone action on tumors.
• SERMs selective estrogen receptor modulators
• anti-estrogens and SERMs examples include tamoxifen (including NOLVADEXTM), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (FARESTON®).
• Examples include 4(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGACE®), exemestane, formestane, fadrozole, vorozole (RIVISOR®), letrozole (FEMARA®), and anastrozole (ARIMIDEX®).
• anti-androgens include apalutamide, abiraterone, enzalutamide, flutamide, galeterone, nilutamide, bicalutamide, leuprolide, goserelin, ODM-201, APC-100, ODM-204, enobosarm (GTX-024), darolutamide, and IONIS-AR-2.5Rx (antisense).
• An example progesterone receptor antagonist includes onapristone. Additional progesterone targeting agents include TRI-CYCLEN LO (norethindrone + ethinyl estradiol), norgestimate + ethinylestradiol (Tri-Cyclen) and levonorgestrel. Anti-Angiogenic Agents [0324] In some embodiments the compound provided herein is administered with an anti- angiogenic agent.
• Anti-angiogenic agents that can be co-administered include retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN®, ENDOSTATIN®, regorafenib, necuparanib, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism including proline analogs such as l-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I- 3,4-dehydroproline,
• anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF, and Ang-1/Ang-2.
• anti-VEGFA antibodies that can be co-administered include bevacizumab, vanucizumab, faricimab, dilpacimab (ABT-165; DLL4/VEGF), or navicixizumab (OMP-305B83; DLL4/VEGF).
• Anti-fibrotic Agents [0325] In some embodiments the compound provided herein is administered with an anti-fibrotic agent.
• Anti-fibrotic agents that can be co-administered include the compounds such as beta- aminoproprionitrile (BAPN), as well as the compounds disclosed in US4965288 relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen and US4997854 relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference.
• BAPN beta- aminoproprionitrile
• Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives; semicarbazide and urea derivatives; aminonitriles such as BAPN or 2-nitroethylamine; unsaturated or saturated haloamines such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3- bromopropylamine, and p-halobenzylamines; and selenohomocysteine lactone.
• primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product
• anti-fibrotic agents are copper chelating agents penetrating or not penetrating the cells.
• Exemplary compounds include indirect inhibitors which block the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases.
• Examples include the thiolamines, particularly D-penicillamine, and its analogs such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2- acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2- acetamidoethanethiol sulphanate, and sodium-4-mercaptobutanesulphinate trihydrate.
• Example anti-inflammatory agents include without limitation inhibitors of one or more of arginase (ARG1 (NCBI Gene ID: 383), ARG2 (NCBI Gene ID: 384)), carbonic anhydrase (CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632)), pros
• the inhibitor is a dual inhibitor, e.g., a dual inhibitor of COX-2/COX-1, COX- 2/SEH, COX-2/CA, COX-2/5-LOX.
• a dual inhibitor of COX-2/COX-1, COX- 2/SEH, COX-2/CA, COX-2/5-LOX examples include mofezolac, GLY-230, and TRK-700.
• inhibitors of prostaglandin-endoperoxide synthase 2 include diclofenac, meloxicam, parecoxib, etoricoxib, AP-101, celecoxib, AXS-06, diclofenac potassium, DRGT-46, AAT-076, meisuoshuli, lumiracoxib, meloxicam, valdecoxib, zaltoprofen, nimesulide, anitrazafen, apricoxib, cimicoxib, deracoxib, flumizole, firocoxib, mavacoxib, NS-398, pamicogrel, parecoxib, robenacoxib, rofecoxib, rutecarpine, tilmacoxib, and zaltoprofen.
• Examples of dual COX1/COX2 inhibitors that can be co-administered include HP-5000, lornoxicam, ketorolac tromethamine, bromfenac sodium, ATB-346, HP-5000.
• Examples of dual COX-2/carbonic anhydrase (CA) inhibitors that can be co-administered include polmacoxib and imrecoxib.
• inhibitors of secreted phospholipase A2, prostaglandin E synthase include LY3023703, GRC 27864, and compounds described in WO2015158204, WO2013024898, WO2006063466, WO2007059610, WO2007124589, WO2010100249, WO2010034796, WO2010034797, WO2012022793, WO2012076673, WO2012076672, WO2010034798, WO2010034799, WO2012022792, WO2009103778, WO2011048004, WO2012087771, WO2012161965, WO2013118071, WO2013072825, WO2014167444, WO2009138376, WO2011023812, WO2012110860, WO2013153535, WO2009130242, WO2009146696, WO2013186692,
• Metformin has further been found to repress the COX2/PGE2/STAT3 axis, and can be co-administered. See, e.g., Tong, et al., Cancer Lett. (2017) 389:23-32; and Liu, et al., Oncotarget. (2016) 7(19):28235-46.
• inhibitors of carbonic anhydrase include acetazolamide, methazolamide, dorzolamide, zonisamide, brinzolamide and dichlorphenamide.
• a dual COX- 2/CA1/CA2 inhibitor that can be co-administered includes CG100649.
• Examples of inhibitors of arachidonate 5-lipoxygenase (ALOX5, 5-LOX; NCBI Gene ID: 240) that can be co-administered include meclofenamate sodium, zileuton.
• Examples of inhibitors of soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053) that can be co-administered include compounds described in WO2015148954.
• Dual inhibitors of COX-2/SEH that can be co-administered include compounds described in WO2012082647.
• Dual inhibitors of SEH and fatty acid amide hydrolase (FAAH; NCBI Gene ID: 2166) that can be co-administered include compounds described in WO2017160861.
• Examples of inhibitors of mitogen-activated protein kinase kinase kinase 8 (MAP3K8, tumor progression loci-2, TPL2; NCBI Gene ID: 1326) that can be co-administered include GS- 4875, GS-5290, BHM-078 and those described in WO2006124944, WO2006124692, WO2014064215, WO2018005435, Teli, et al., J Enzyme Inhib Med Chem.
• Tumor Oxygenation Agents [0336]
• the compound provided herein is administered with an agent that promotes or increases tumor oxygenation or reoxygenation, or prevents or reduces tumor hypoxia.
• Illustrative agents that can be co-administered include, e.g., Hypoxia inducible factor-1 alpha (HIF-1 ⁇ ) inhibitors, such as PT-2977, PT-2385; VEGF inhibitors, such as bevasizumab, IMC- 3C5, GNR-011, tanibirumab, LYN-00101, ABT-165; and/or an oxygen carrier protein (e.g., a heme nitric oxide and/or oxygen binding protein (HNOX)), such as OMX-302 and HNOX proteins described in WO2007137767, WO2007139791, WO2014107171, and WO2016149562.
• HNF-1 ⁇ Hypoxia inducible factor-1 alpha
• HIF-1 ⁇ Hypoxia inducible factor-1 alpha
• VEGF inhibitors such as bevasizumab, IMC- 3C5, GNR-011, tanibirumab, LYN-00101, ABT-165
• the compound provided herein is administered with an immunotherapeutic agent.
• the immunotherapeutic agent is an antibody.
• Example immunotherapeutic agents that can be co-administered include abagovomab, AB308, ABP-980, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, atezolizumab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, camidanlumab, cantuzumab, catumaxomab, CC49, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, dacetuzuma
• Rituximab can be used for treating indolent B-cell cancers, including marginal-zone lymphoma, WM, CLL, and small lymphocytic lymphoma. A combination of rituximab and chemotherapy agents is especially effective.
• the exemplified therapeutic antibodies can be further labeled or combined with a radioisotope particle such as indium-111, yttrium-90 (90Y-clivatuzumab), or iodine-131.
• the immunotherapeutic agent is an antibody-drug conjugate (ADC).
• Illustrative ADCs that can be co-administered include without limitation drug-conjugated antibodies, fragments thereof, or antibody mimetics targeting the proteins or antigens listed above and herein.
• Example ADCs that can be co-administered include gemtuzumab, brentuximab, belantamab (e.g., belantamab mafodotin), camidanlumab (e.g., camidanlumab tesirine), trastuzumab (e.g., trastuzumab deruxtecan; trasuzumab emtansine), inotuzumab, glembatumumab, anetumab, mirvetuximab (e.g., mirvetuximab soravtansine), depatuxizumab, vadastuximab, labetuzumab, ladiratuzumab (e.g., ladiratuzum
• ADCs that can be co-administered are described, e.g., in Lambert, et al., Adv Ther (2017) 34:1015–1035 and in de Goeij, Current Opinion in Immunology (2016) 40:14–23.
• Illustrative therapeutic agents that can be conjugated to the drug-conjugated antibodies, fragments thereof, or antibody mimetics include without limitation monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), a calicheamicin, ansamitocin, maytansine or an analog thereof (e.g., mertansine/emtansine (DM1), ravtansine/soravtansine (DM4)), an anthracyline (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin), pyrrolobenzodiazepine (PBD) DNA cross-linking agent SC-DR002 (D6.5), duocarmycin, a microtubule inhibitors (MTI) (e.g., a taxane, a vinca alkaloid, an epothilone), a pyrrolobenz
• the therapeutic agent conjugated to the drug-conjugated antibody is a topoisomerase I inhibitor (e.g., a camptothecin analog, such as irinotecan or its active metabolite SN38).
• the therapeutic agents e.g., anticancer or antineoplastic agents
• the conjugated immune checkpoint inhibitor is a conjugated small molecule inhibitor of CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD- 1) or CTLA4.
• the conjugated small molecule inhibitor of CD274 or PDCD1 is selected from the group consisting of GS-4224, GS-4416, INCB086550 and MAX10181.
• the conjugated small molecule inhibitor of CTLA4 comprises BPI-002.
• the ADCs that can be co-administered include an antibody targeting tumor-associated calcium signal transducer 2 (TROP-2; TACSTD2; EGP-1; NCBI Gene ID: 4070).
• Illustrative anti-TROP-2 antibodies include without limitation TROP2-XPAT (Amunix), BAT-8003 (Bio-Thera Solutions), TROP-2-IR700 (Chiome Bioscience), datopotamab deruxtecan (Daiichi Sankyo, AstraZeneca), GQ-1003 (Genequantum Healthcare, Samsung BioLogics), DAC-002 (Hangzhou DAC Biotech, Shanghai Junshi Biosciences), sacituzumab govitecan (Gilead Sciences), E1-3s (Immunomedics/Gilead, IBC Pharmaceuticals), TROP2-TRACTr (Janux Therapeutics), LIV-2008 (LivTech/Chiome, Yakult Honsha, Shanghai Henlius BioTech), LIV-2008b (LivTech/Chiome), anti-TROP-2a (Oncoxx), anti-TROP-2b (Oncoxx), OXG-64 (Oncoxx), OXS-55 (Oncoxx), humanized anti-T
• the anti-Trop-2 antibody is selected from hRS7, Trop-2- XPAT, and BAT-8003.
• the anti-Trop-2 antibody is hRS7.
• hRS7 is as disclosed in U.S. Pat. Nos. 7,238,785; 7,517,964 and 8,084,583, which are incorporated herein by reference.
• the antibody-drug conjugate comprises an anti-Trop-2 antibody and an anticancer agent linked by a linker.
• the linker includes the linkers disclosed in USPN 7,999,083.
• the linker is CL2A.
• the drug moiety of antibody-drug conjugate is a chemotherapeutic agent.
• the chemotherapeutic agent is selected from doxorubcin (DOX), epirubicin, morpholinodoxorubicin (morpholino-DOX), cyanomorpholino- doxorubicin (cyanomorpholino-DOX), 2-pyrrolino-doxorubicin (2-PDOX), CPT, 10-hydroxy camptothecin, SN-38, topotecan, lurtotecan, 9-aminocamptothecin, 9-nitrocamptothecin, taxanes, geldanamycin, ansamycins, and epothilones.
• DOX doxorubcin
• epirubicin morpholinodoxorubicin
• morpholino-DOX morpholino-DOX
• cyanomorpholino- doxorubicin cyanomorpholino-DOX
• the chemotherapeutic moiety is SN-38.
• the compound provided herein is administered with sacituzumab govitecan.
• the ADCs that can be co-administered include an antibody targeting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1; CD66a; NCBI Gene ID: 634).
• CEACAM1 antibody is hMN-14 (e.g., as described in WO1996011013).
• the CEACAM1-ADC is as described in WO2010093395 (anti-CEACAM-1-CL2A-SN38).
• the compound provided herein is administered with the CEACAM1-ADC IMMU-130.
• the ADCs that can be co-administered include an antibody targeting MHC class II cell surface receptor encoded by the human leukocyte antigen complex (HLA-DR).
• HLA-DR antibody is hL243 (e.g., as described in WO2006094192).
• HLA-DR-ADC is as described in WO2010093395 (anti-HLA-DR-CL2A- SN38).
• the compound provided herein is administered with the HLA-DR- ADC IMMU-140.
• Cancer Gene Therapy and Cell Therapy [0344]
• the compound provided herein is administered with a cancer gene therapy and cell therapy.
• Cancer gene therapies and cell therapies include the insertion of a normal gene into cancer cells to replace a mutated or altered gene; genetic modification to silence a mutated gene; genetic approaches to directly kill the cancer cells; including the infusion of immune cells designed to replace most of the patient’s own immune system to enhance the immune response to cancer cells, or activate the patient’s own immune system (T cells or Natural Killer cells) to kill cancer cells, or find and kill the cancer cells; genetic approaches to modify cellular activity to further alter endogenous immune responsiveness against cancer.
• Cellular Therapies [0345]
• the compound provided herein is administered with one or more cellular therapies.
• Illustrative cellular therapies include without limitation co-administration of one or more of a population of natural killer (NK) cells, NK-T cells, T cells, cytokine-induced killer (CIK) cells, macrophage (MAC) cells, tumor infiltrating lymphocytes (TILs) and/or dendritic cells (DCs).
• the cellular therapy entails a T cell therapy, e.g., co- administering a population of alpha/beta TCR T cells, gamma/delta TCR T cells, regulatory T (Treg) cells and/or TRuCTM T cells.
• the cellular therapy entails a NK cell therapy, e.g., co-administering NK-92 cells.
• a cellular therapy can entail the co- administration of cells that are autologous, syngeneic or allogeneic to the subject.
• the cellular therapy entails co-administering cells comprising chimeric antigen receptors (CARs).
• CARs chimeric antigen receptors
• TCRs T cell receptors
• TCRs are engineered to target tumor derived peptides presented on the surface of tumor cells.
• the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
• the intracellular domain comprises a primary signaling domain, a costimulatory domain, or both of a primary signaling domain and a costimulatory domain.
• the primary signaling domain comprises a functional signaling domain of one or more proteins selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon Rlb), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12.
• a functional signaling domain of one or more proteins selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta (Fc Epsilon Rlb), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12.
• the costimulatory domain comprises a functional domain of one or more proteins selected from the group consisting of CD27, CD28, 4-1BB(CD137), OX40, CD30, CD40, PD-1, ICOS, CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRFI), CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, CD103, ITGAL, CD1A (NCBI Gene ID: 909), CD1B (NCBI Gene ID: 910), CD1C (NCBI Gene ID: 911), CD
• the transmembrane domain comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, ICOS (CD278), 4-1BB(CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1A, CD1B, CD1C, CD1D, CD1E, ITGAE,
• the TCR or CAR antigen binding domain or the immunotherapeutic agent described herein binds a tumor-associated antigen (TAA).
• TAA tumor-associated antigen
• the tumor-associated antigen is selected from the group consisting of: CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvlll); ganglioside G2 (GD2); ganglioside GD3 ( ⁇ NeuSAc(2-8) ⁇ NeuSAc(2-3) ⁇ DGaip(1- 4)bDGIcp(1-1)Cer); ganglioside GM3 ( ⁇ NeuSAc(2-3) ⁇ DGalp(1-4) ⁇ DGlcp(1-1)Cer); TNF receptor superfamily member 17 (TNFRSF17, BCMA); Tn antigen ((Tn Ag) or (GaINAcu- Ser/Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinas
• the target is an epitope of the tumor associated antigen presented in an MHC.
• the tumor antigen is selected from CD150, 5T4, ActRIIA, B7, TNF receptor superfamily member 17 (TNFRSF17, BCMA), CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, HER1-HER2 in combination
• the antigen binding domain binds to an epitope of a target or tumor associated antigen (TAA) presented in a major histocompatibility complex (MHC) molecule.
• TAA tumor associated antigen
• MHC major histocompatibility complex
• the TAA is a cancer testis antigen.
• the cancer testis antigen is selected from the group consisting of acrosin binding protein (ACRBP; CT23, OY- TES-1, SP32; NCBI Gene ID: 84519), alpha fetoprotein (AFP; AFPD, FETA, HPAFP; NCBI Gene ID: 174); A-kinase anchoring protein 4 (AKAP4; AKAP 82, AKAP-4, AKAP82, CT99, FSC1, HI, PRKA4, hAKAP82, p82; NCBI Gene ID: 8852), ATPase family AAA domain containing 2 (ATAD2; ANCCA, CT137, PRO2000; NCBI Gene ID: 29028), kinetochore scaffold 1 (KNL1; AF15Q14, CASC5, CT29, D40, MCPH4, PPP1R55, Spc7, hKNL-1, hSpc105; NCBI Gene ID: 57082), centrosomal protein 55 (CEP55; C10
• T cell receptors TCRs
• MHC major histocompatibility complex
• TCRs and TCR-like antibodies that bind to an epitope of NY-ESO-1 presented in an MHC are described, e.g., in Stewart-Jones, et al., Proc Natl Acad Sci USA. 2009 Apr 7;106(14):5784-8; WO2005113595, WO2006031221, WO2010106431, WO2016177339, WO2016210365, WO2017044661, WO2017076308, WO2017109496, WO2018132739, WO2019084538, WO2019162043, WO2020086158 and WO2020086647.
• TCRs and TCR-like antibodies that bind to an epitope of PRAME presented in an MHC are described, e.g., in WO2011062634, WO2016142783, WO2016191246, WO2018172533, WO2018234319 and WO2019109821.
• TCRs and TCR-like antibodies that bind to an epitope of a MAGE variant presented in an MHC are described, e.g., in WO2007032255, WO2012054825, WO2013039889, WO2013041865, WO2014118236, WO2016055785, WO2017174822, WO2017174823, WO2017174824, WO2017175006, WO2018097951, WO2018170338, WO2018225732 and WO2019204683.
• Illustrative TCRs and TCR-like antibodies that bind to an epitope of alpha fetoprotein (AFP) presented in an MHC are described, e.g., in WO2015011450.
• TCRs and TCR-like antibodies that bind to an epitope of SSX2 presented in an MHC are described, e.g., in WO2020063488.
• Illustrative TCRs and TCR-like antibodies that bind to an epitope of KK-LC-1 (CT83) presented in an MHC are described, e.g., in WO2017189254.
• Examples of cell therapies include: Algenpantucel-L, Sipuleucel-T, (BPX-501) rivogenlecleucel US9089520, WO2016100236, AU-105, ACTR-087, activated allogeneic natural killer cells CNDO-109-AANK, MG-4101, AU-101, BPX-601, FATE-NK100, LFU-835 hematopoietic stem cells, Imilecleucel-T, baltaleucel-T, PNK-007, UCARTCS1, ET-1504, ET- 1501, ET-1502, ET-190, CD19-ARTEMIS, ProHema, FT-1050-treated bone marrow stem cell therapy, CD4CARNK-92 cells, CryoStim, AlloStim, lentiviral transduced huCART-meso cells, CART-22 cells, EGFRt/19-28z/4-1BBL CAR T cells, autologous 4H11-28z/fIL-12
• the one or more additional co-administered therapeutic agents can be categorized by their mechanism of action, e.g., into the following groups: • agents targeting adenosine deaminase, such as pentostatin or cladribine; • agents targeting ATM, such as AZD1390; • agents targeting MET, such as savolitinib, capmatinib, tepotinib, ABT-700, AG213, JNJ- 38877618 (OMO-1), merestinib, HQP-8361, BMS-817378, or TAS-115; • agents targeting mitogen-activated protein kinase, such as antroquinonol, binimetinib, cobimetinib, selumetinib, trametinib, uprosertib, mirdametinib (PD-0325901), pimasertib, refametinib, or
• agents targeting thymidine kinase such as aglatimagene besadenovec (ProstAtak, PancAtak, GliAtak, GMCI, or AdV-tk); • agents targeting targeting an interleukin pathway, such as pegilodecakin (AM-0010) (pegylated IL10), CA-4948 (IRAK4 inhibitor); • agents targeting cytochrome P450 family members, such as letrozole, anastrozole, aminoglutethimide, megestrol acetate (MEGACE®), exemestane, formestane, fadrozole, vorozole (RIVISOR®), letrozole (FEMARA®), or anastrozole (ARIMIDEX®); • agents targeting CD73, such as a CD73 inhibitor (e.g., quemliclustat (AB680)) or an anti- CD73 antibody (e.g.,
• Some chemotherapy agents are suitable for treating lymphoma or leukemia. These agents include aldesleukin, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, Bcl-2 family protein inhibitor ABT-263, beta alethine, BMS-345541, bortezomib (VELCADE®), bortezomib (VELCADE®, PS-341), bryostatin 1, bulsulfan, campath-1H, carboplatin, carfilzomib (Kyprolis®), carmustine, caspofungin acetate, CC-5103, chlorambucil, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), cisp
• Radioimmunotherapy wherein a monoclonal antibody is combined with a radioisotope particle, such as indium-111, yttrium-90, and iodine-131.
• a radioisotope particle such as indium-111, yttrium-90, and iodine-131.
• combination therapies include, but are not limited to, iodine-131 tositumomab (BEXXAR®), yttrium-90 ibritumomab tiuxetan (ZEVALIN®), and BEXXAR® with CHOP.
• BEXXAR® iodine-131 tositumomab
• ZEVALIN® yttrium-90 ibritumomab tiuxetan
• BEXXAR® with CHOP.
• Therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
• Non-Hodgkin’s lymphomas Combination Therapy Treatment of non-Hodgkin’s lymphomas (NHL), especially those of B cell origin, includes using monoclonal antibodies, standard chemotherapy approaches (e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and prednisone), FCM (fludarabine, cyclophosphamide, and mitoxantrone), MCP (Mitoxantrone, Chlorambucil, Prednisolone), all optionally including rituximab (R) and the like), radioimmunotherapy, and combinations thereof, especially integration of an antibody therapy with chemotherapy.
• standard chemotherapy approaches e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and pre
• Examples of unconjugated monoclonal antibodies for the treatment of NHL/B-cell cancers include rituximab, alemtuzumab, human or humanized anti-CD20 antibodies, lumiliximab, anti- TNF-related apoptosis-inducing ligand (anti-TRAIL), bevacizumab, galiximab, epratuzumab, SGN-40, and anti-CD74.
• Examples of experimental antibody agents used in treatment of NHL/B-cell cancers include ofatumumab, ha20, PRO131921, alemtuzumab, galiximab, SGN-40, CHIR-12.12, epratuzumab, lumiliximab, apolizumab, milatuzumab, and bevacizumab.
• Examples of standard regimens of chemotherapy for NHL/B-cell cancers include CHOP, FCM, CVP, MCP, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-FCM, R-CVP, and R MCP.
• Examples of radioimmunotherapy for NHL/B-cell cancers include yttrium-90 ibritumomab tiuxetan (ZEVALIN®) and iodine-131 tositumomab (BEXXAR®).
• Mantle Cell Lymphoma Combination Therapy [0363] Therapeutic treatments for mantle cell lymphoma (MCL) include combination chemotherapies such as CHOP, hyperCVAD, and FCM. These regimens can also be supplemented with the monoclonal antibody rituximab to form combination therapies R-CHOP, hyperCVAD-R, and R-FCM.
• any of the abovementioned therapies may be combined with stem cell transplantation or ICE in order to treat MCL.
• An alternative approach to treating MCL is immunotherapy.
• One immunotherapy uses monoclonal antibodies like rituximab.
• a modified approach to treat MCL is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as iodine-131 tositumomab (BEXXAR®) and yttrium-90 ibritumomab tiuxetan (ZEVALIN®).
• BEXXAR® is used in sequential treatment with CHOP.
• Other approaches to treating MCL include autologous stem cell transplantation coupled with high-dose chemotherapy, administering proteasome inhibitors such as bortezomib (VELCADE® or PS-341), or administering antiangiogenesis agents such as thalidomide, especially in combination with rituximab.
• Another treatment approach is administering drugs that lead to the degradation of Bcl-2 protein and increase cancer cell sensitivity to chemotherapy, such as oblimersen, in combination with other chemotherapeutic agents.
• a further treatment approach includes administering mTOR inhibitors, which can lead to inhibition of cell growth and even cell death.
• Non-limiting examples are sirolimus, temsirolimus (TORISEL®, CCI-779), CC-115, CC-223, SF-1126, PQR-309 (bimiralisib), voxtalisib, GSK- 2126458, and temsirolimus in combination with RITUXAN®, VELCADE®, or other chemotherapeutic agents.
• TORISEL® temsirolimus
• CCI-779 CCI-779
• CC-115 CC-223, SF-1126
• PQR-309 bimiralisib
• voxtalisib voxtalisib
• GSK- 2126458 temsirolimus in combination with RITUXAN®, VELCADE®, or other chemotherapeutic agents.
• Other recent therapies for MCL have been disclosed.
• Such examples include flavopiridol, palbociclib (PD0332991), R-roscovitine (selicicilib, CYC202), styryl sulphones, obatoclax (GX15-070), TRAIL, Anti-TRAIL death receptors DR4 and DR5 antibodies, temsirolimus (TORISEL®, CCl-779), everolimus (RAD001), BMS-345541, curcumin, SAHA, thalidomide, lenalidomide (REVLIMID®, CC-5013), and geldanamycin (17 AAG).
• WM Macroglobulinemia Combination Therapy
• agents used to treat Waldenstrom’s Macroglobulinemia include aldesleukin, alemtuzumab, alvocidib, amifostine trihydrate, aminocamptothecin, antineoplaston A10, antineoplaston AS2-1, anti-thymocyte globulin, arsenic trioxide, autologous human tumor- derived HSPPC-96, Bcl-2 family protein inhibitor ABT-263, beta alethine, bortezomib (VELCADE®), bryostatin 1, busulfan, campath-1H, carboplatin, carmustine, caspofungin acetate, CC-5103, cisplatin, clofarabine, cyclophosphamide, cyclosporine, cytarabine, denileukin diftitox, dexamethasone, docetaxel, dolastatin 10, dox
• Examples of therapeutic procedures used to treat WM include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme techniques, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
• Diffuse Large B-cell Lymphoma Combination Therapy
• Therapeutic agents used to treat diffuse large B-cell lymphoma include cyclophosphamide, doxorubicin, vincristine, prednisone, anti-CD20 monoclonal antibodies, etoposide, bleomycin, many of the agents listed for WM, and any combination thereof, such as ICE and RICE.
• therapeutic agents used to treat DLBCL include rituximab (Rituxan®), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin®), prednisone, bendamustine, ifosfamide, carboplatin, etoposide, ibrutinib, polatuzumab vedotin piiq, bendamustine, copanlisib, lenalidomide (Revlimid®), dexamethasone, cytarabine, cisplatin, Yescarta®, Kymriah®, Polivy®(polatuzumab vedotin), BR (bendamustine (Treanda®), gemcitabine, oxiplatin, oxaliplatin, tafasitamab, polatuzumab, cyclopho
• therapeutic agents used to treat DLBCL include R- CHOP (rituximab + cyclophosphamide + doxorubicin hydrochloride (hydroxydaunorubicin)+ vincristine sulfate (Oncovin®), + prednisone), rituximab + bendamustine, R-ICE (Rituximab + Ifosfamide + Carboplatin + Etoposide), rituximab + lenalomide, R-DHAP (rituximab + dexamethasone + high-dose cytarabine (Ara C) + cisplatin), Polivy®(polatuzumab vedotin) +BR (bendamustine (Treanda®) and rituximab (Rituxan®), R-GemOx (Gemcitabine + oxaliplatin + rituximab), Tafa-L
• therapeutic agents used to treat DLBCL include tafasitamab, glofitamab, epcoritamab, Lonca-T (loncastuximab tesirine), Debio-1562, polatuzumab, Yescarta, JCAR017, ADCT-402, brentuximab vedotin, MT-3724, odronextamab , Auto-03, Allo-501A, or TAK-007.
• Chronic Lymphocytic Leukemia Combination Therapy Therapeutic agents used to treat chronic lymphocytic leukemia (CLL) include chlorambucil, cyclophosphamide, fludarabine, pentostatin, cladribine, doxorubicin, vincristine, prednisone, prednisolone, alemtuzumab, many of the agents listed for WM, and combination chemotherapy and chemoimmunotherapy, including the following common combination regimens: CVP, R-CVP, ICE, R-ICE, FCR, and FR.
• CLL chronic lymphocytic leukemia
• HR MDS High Risk Myelodysplastic Syndrome
• Therapeutic agents used to treat HR MDS include azacitidine (Vidaza®), decitabine (Dacogen®), lenalidomide (Revlimid®), cytarabine, idarubicin, daunorubicin, and combinations thereof. In some embodiments combinations include cytarabine + daunorubicin and cytarabine + idarubicin.
• therapeutic agents used to treat HR MDS include pevonedistat, venetoclax, sabatolimab, guadecitabine, rigosertib, ivosidenib, enasidenib, selinexor, BGB324, DSP-7888, or SNS-301.
• Low Risk Myelodysplastic Syndrome (LR MDS) Combination Therapy Therapeutic agents used to treat LR MDS include lenalidomide, azacytidine, and combinations thereof.
• therapeutic agents used to treat LR MDS include roxadustat, luspatercept, imetelstat, LB-100, or rigosertib.
• HR MDS High Risk Myelodysplastic Syndrome
• Therapeutic agents used to treat HR MDS include azacitidine (Vidaza®), decitabine (Dacogen®), lenalidomide (Revlimid®), cytarabine, idarubicin, daunorubicin, and combinations thereof. In some embodiments combinations include cytarabine + daunorubicin and cytarabine + idarubicin.
• therapeutic agents used to treat HR MDS include pevonedistat, venetoclax, sabatolimab, guadecitabine, rigosertib, ivosidenib, enasidenib, selinexor, BGB324, DSP-7888, or SNS-301.
• Low Risk Myelodysplastic Syndrome (LR MDS) Combination Therapy Therapeutic agents used to treat LR MDS include lenalidomide, azacytidine, and combinations thereof.
• therapeutic agents used to treat LR MDS include roxadustat, luspatercept, imetelstat, LB-100, or rigosertib.
• AML Acute Myeloid Leukemia
• Therapautic agents used to treat AML include cytarabine, idarubicin, daunorubicin, midostaurin (Rydapt®), venetoclax, azacitidine, ivasidenib, gilteritinib, enasidenib, low-dose cytarabine (LoDAC), mitoxantrone, fludarabine, granulocyte-colony stimulating factor, idarubicin, gilteritinib (Xospata®), enasidenib (Idhifa®), ivosidenib (Tibsovo®), decitabine (Dacogen®), mitoxantrone, etoposide, Gemtuzumab ozogamicin (Mylotarg®), glasdegib (Daurismo®), and combinations thereof.
• therapeutic agents used to treat AML include FLAG- Ida (fludarabine, cytarabine (Ara-C), granulocyte- colony stimulating factor (G-CSF) and idarubicin), cytarabine + idarubicin, cytarabine + daunorubicin + midostaurin, venetoclax + azacitidine, cytarabine + daunorubicin, or MEC (mitoxantrone, etoposide, and cytarabine).
• therapeutic agents used to treat AML include pevonedistat, venetoclax, sabatolimab, eprenetapopt, or lemzoparlimab.
• Multiple Myeloma (MM) Combination Therapy [0379] Therapeutic agents used to treat MM include lenalidomide, bortezomib, dexamethasone, daratumumab (Darzalex®), pomalidomide, Cyclophosphamide, Carfilzomib (Kyprolis®), Elotuzumab (Empliciti), and combinations thereof.
• therapeutic agents used to treat MM include RVS (lenalidomide + bortezomib + dexamethasone), RevDex (lenalidomide plus dexamethasone), CYBORD (Cyclophosphamide+Bortezomib+Dexamethasone), Vel/Dex (bortezomib plus dexamethasone), or PomDex (Pomalidomide + low-dose dexamethasone).
• therapeutic agents used to treat MM include JCARH125, TAK-573, belantamab-m, ide-cel (CAR-T).
• Therapeutic agents used to treat breast cancer include albumin-bound paclitaxel, anastrozole, atezolizumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin, everolimus, exemestane, fluorouracil, fulvestrant, gemcitabine, Ixabepilone, lapatinib, letrozole, methotrexate, mitoxantrone, paclitaxel, pegylated liposomal doxorubicin, pertuzumab, tamoxifen, toremifene, trastuzumab, vinorelbine, and any combinations thereof.
• therapeutic agents used to treat breast cancer include trastuzumab (Herceptin ® ), pertuzumab (Perjeta ® ), docetaxel, carboplatin, palbociclib (Ibrance ® ), letrozole, trastuzumab emtansine (Kadcyla ® ), fulvestrant (Faslodex ® ), olaparib (Lynparza ® ), eribulin, tucatinib, capecitabine, lapatinib, everolimus (Afinitor ® ), exemestane, eribulin mesylate (Halaven ® ), and combinations thereof.
• therapeutic agents used to treat breast cancer include trastuzumab + pertuzumab + docetaxel, trastuzumab + pertuzumab + docetaxel + carboplatin, palbociclib + letrozole, tucatinib + capecitabine, lapatinib + capecitabine, palbociclib + fulvestrant, or everolimus + exemestane.
• therapeutic agents used to treat breast cancer include trastuzumab deruxtecan (Enhertu ® ), datopotamab deruxtecan (DS-1062), enfortumab vedotin (Padcev ® ), balixafortide, elacestrant, or a combination thereof.
• therapeutic agents used to treat breast cancer include balixafortide + eribulin.
• Triple Negative Breast Cancer (TNBC) Combination Therapy [0381]
• Therapeutic agents used to treat TNBC include atezolizumab, cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil, paclitaxel, and combinations thereof.
• therapeutic agents used to treat TNBC include olaparib (Lynparza ® ), atezolizumab (Tecentriq ® ), paclitaxel (Abraxane ® ), eribulin, bevacizumab (Avastin ® ), carboplatin, gemcitabine, eribulin mesylate (Halaven ® ), sacituzumab govitecan (Trodelvy ® ), pembrolizumab (Keytruda ® ), cisplatin, doxorubicin, epirubicin, or a combination thereof.
• therapeutic agents to treat TNBC include atezolizumab + paclitaxel, bevacizumab + paclitaxel, carboplatin + paclitaxel, carboplatin + gemcitabine, or paclitaxel + gemcitabine.
• therapeutic agents used to treat TNBC include eryaspase, capivasertib, alpelisib, rucaparib + nivolumab, atezolumab + paclitaxel + gemcitabine+ capecitabine + carboplatin, ipatasertib + paclitaxel, ladiratuzumab vedotin + pembrolimab, durvalumab + DS-8201a, trilaciclib + gemcitabine +carboplatin.
• therapeutic agents used to treat TNBC include trastuzumab deruxtecan (Enhertu ® ), datopotamab deruxtecan (DS-1062), enfortumab vedotin (Padcev ® ), balixafortide, adagloxad simolenin, nelipepimut-s (NeuVax ® ), nivolumab (Opdivo ® ), rucaparib, toripalimab (Tuoyi ® ), camrelizumab, capivasertib, durvalumab (Imfinzi ® ), and combinations thereof.
• therapeutic agents use to treat TNBC include nivolumab + rucaparib, bevacizumab (Avastin ® ) + chemotherapy, toripalimab + paclitaxel, toripalimab + albumin-bound paclitaxel, camrelizumab + chemotherapy, pembrolizumab + chemotherapy, balixafortide + eribulin, durvalumab + trastuzumab deruxtecan, durvalumab + paclitaxel, or capivasertib + paclitaxel.
• nivolumab + rucaparib bevacizumab (Avastin ® ) + chemotherapy
• toripalimab + paclitaxel toripalimab + albumin-bound paclitaxel
• camrelizumab + chemotherapy pembrolizumab + chemotherapy
• balixafortide + eribulin durvalumab + trastuzumab deruxtecan
• Bladder Cancer Combination Therapy [0382] Therapeutic agents used to treat bladder cancer include datopotamab deruxtecan (DS- 1062), trastuzumab deruxtecan (Enhertu ® ), erdafitinib, eganelisib, lenvatinib, bempegaldesleukin (NKTR-214), or a combination thereof.
• DS- 1062 datopotamab deruxtecan
• Enhertu ® trastuzumab deruxtecan
• erdafitinib eganelisib
• lenvatinib bempegaldesleukin
• therapeutic agents used to treat bladder cancer include eganelisib + nivolumab, pembrolizumab (Keytruda ® ) + enfortumab vedotin (Padcev ® ), nivolumab + ipilimumab, duravalumab + tremelimumab, lenvatinib + pembrolizumab, enfortumab vedotin (Padcev ® ) + pembrolizumab, and bempegaldesleukin + nivolumab.
• CRC Colorectal Cancer
• Therapeutic agents used to treat CRC include bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, and any combinations thereof.
• therapeutic agents used to treat CRC include bevacizumab (Avastin ® ), leucovorin, 5-FU, oxaliplatin (FOLFOX), pembrolizumab (Keytruda ® ), FOLFIRI, regorafenib (Stivarga ® ), aflibercept (Zaltrap ® ), cetuximab (Erbitux ® ), Lonsurf (Orcantas ® ), XELOX, FOLFOXIRI, or a combination thereof.
• bevacizumab Avastin ®
• leucovorin 5-FU
• FOLFOX oxaliplatin
• pembrolizumab Keytruda ®
• FOLFIRI fluorafenib
• tivarga ® aflibercept
• cetuximab Erbitux ®
• Lonsurf Orcantas ®
• XELOX FOLFOXIRI
• therapeutic agents used to treat CRC include bevacizumab + leucovorin + 5-FU, bevacizumab + leucovorin + 5-FU + oxaliplatin (FOLFOX), bevacizumab + FOLFIRI, bevacizumab + FOLFOX, aflibercept + FOLFIRI, cetuximab + FOLFIRI, cetuximab + FOLFOX, bevacizumab + XELOX, and bevacizumab + FOLFOXIRI.
• FOLFOX oxaliplatin
• therapeutic agents used to treat CRC include binimetinib + encorafenib + cetuximab, trametinib + dabrafenib + panitumumab, trastuzumab + pertuzumab, napabucasin + FOLFIRI + bevacizumab, nivolumab + ipilimumab.
• Therapeutic agents used to treat esophageal and esophagogastric junction cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, irinotecan, leucovorin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.
• therapeutic agents used to treat gastroesophageal junction cancer (GEJ) include herceptin, cisplatin, 5-FU, ramicurimab, or paclitaxel.
• therapeutic agents used to treat GEJ cancer include ALX-148, AO-176, or IBI-188.
• Gastric Cancer Combination Therapy [0385] Therapeutic agents used to treat gastric cancer include capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, fluoropyrimidine, fluorouracil, Irinotecan, leucovorin, mitomycin, oxaliplatin, paclitaxel, ramucirumab, trastuzumab, and any combinations thereof.
• Therapeutic agents used to treat head & neck cancer include afatinib, bleomycin, capecitabine, carboplatin, cetuximab, cisplatin, docetaxel, fluorouracil, gemcitabine, hydroxyurea, methotrexate, nivolumab, paclitaxel, pembrolizumab, vinorelbine, and any combinations thereof.
• Therapeutic agents used to treat head and neck squamous cell carcinoma include pembrolizumab, carboplatin, 5-FU, docetaxel, cetuximab (Erbitux ® ), cisplatin, nivolumab (Opdivo ® ), and combinations thereof.
• therapeutic agents used to treat HNSCC include pembrolizumab + carboplatin + 5-FU, cetuximab + cisplatin + 5-FU, cetuximab + carboplatin + 5-FU, cisplatin + 5-FU, and carboplatin + 5-FU.
• therapeutic agents used to treat HNSCC include durvalumab, durvalumab + tremelimumab, nivolumab + ipilimumab, rovaluecel, pembrolizumab, pembrolizumab + epacadostat, GSK3359609 + pembrolizumab, lenvatinib + pembrolizumab, retifanlimab, retifanlimab + enobituzumab, ADU- S100 + pembrolizumab, epacadostat + nivolumab+ ipilimumab/lirilumab.
• Non-Small Cell Lung Cancer Combination Therapy include afatinib, albumin-bound paclitaxel, alectinib, atezolizumab, bevacizumab, bevacizumab, cabozantinib, carboplatin, cisplatin, crizotinib, dabrafenib, docetaxel, erlotinib, etoposide, gemcitabine, nivolumab, paclitaxel, pembrolizumab, pemetrexed, ramucirumab, trametinib, trastuzumab, vandetanib, vemurafenib, vinblastine, vinorelbine, and any combinations thereof.
• NSCLC non-small cell lung cancer
• therapeutic agents used to treat NSCLC include alectinib (Alecensa ® ), dabrafenib (Tafinlar ® ), trametinib (Mekinist ® ), osimertinib (Tagrisso ® ), entrectinib (Tarceva ® ), crizotinib (Xalkori ® ), pembrolizumab (Keytruda ® ), carboplatin, pemetrexed (Alimta ® ), nab-paclitaxel (Abraxane ® ), ramucirumab (Cyramza ® ), docetaxel, bevacizumab (Avastin ® ), brigatinib, gemcitabine, cisplatin, afatinib (Gilotrif ® ), nivolumab (Opdivo ® ), gefitinib (Iressa
• therapeutic agents used to treat NSCLC include dabrafenib + trametinib, pembrolizumab + carboplatin + pemetrexed, pembrolizumab + carboplatin + paclitaxel, pembrolizumab + carboplatin + nab-paclitaxel, ramucirumab + docetaxel, bevacizumab + carboplatin + pemetrexed, pembrolizumab + pemetrexed + cisplatin, cisplatin + pemetrexed, bevacizumab + carboplatin + nab-paclitaxel, cisplatin + gemcitabine, nivolumab + docetaxel, nivolumab + ipilimumab, carboplatin + pemetrexed, carboplatin + nab- paclitaxel, or pemetrexed + cisplatin + carboplatin.
• therapeutic agents used to NSCLC include datopotamab deruxtecan (DS-1062), ipilimumab, trastuzumab deruxtecan (Enhertu ® ), enfortumab vedotin (Padcev ® ), durvalumab, canakinumab, cemiplimab, nogapendekin alfa, avelumab, tiragolumab, domvanalimab, vibostolimab, ociperlimab, or a combination thereof.
• DS-1062 datopotamab deruxtecan
• ipilimumab trastuzumab deruxtecan
• Enhertu ® enfortumab vedotin
• durvalumab canakinumab
• cemiplimab nogapendekin alfa
• avelumab avelumab
• tiragolumab
• therapeutic agents used to treat NSCLC include datopotamab deruxtecan + pembrolizumab, datopotamab deruxtecan + durvalumab, durvalumab + tremelimumab, pembrolizumab + lenvatinib + pemetrexed, pembrolizumab + olaparib, nogapendekin alfa (N-803) + pembrolizumab, tiragolumab + atezolizumab, vibostolimab + pembrolizumab, or ociperlimab + tislelizumab.
• SCLC Small Cell Lung Cancer Combination Therapy
• Therapeutic agents used to treat small cell lung cancer include atezolizumab, bendamustime, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, ipillimumab, irinotecan, nivolumab, paclitaxel, temozolomide, topotecan, vincristine, vinorelbine, and any combinations thereof.
• therapeutic agents used to treat SCLC include atezolizumab, carboplatin, cisplatin, etoposide, paclitaxel, topotecan, nivolumab, durvalumab, trilaciclib, or combinations thereof.
• therapeutic agents used to treat SCLC include atezolizumab + carboplatin + etoposide, atezolizumab + carboplatin, atezolizumab + etoposide, or carboplatin + paclitaxel.
• Therapeutic agents used to treat ovarian cancer include 5-flourouracil, albumin bound paclitaxel, altretamine, anastrozole, bevacizumab, capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, exemestane, gemcitabine, ifosfamide, irinotecan, letrozole, leuprolide acetate, liposomal doxorubicin, megestrol acetate, melphalan, olaparib, oxaliplatin, paclitaxel, pazopanib, pemetrexed, tamoxifen, topotecan, vinorelbine, and any combinations thereof.
• Therapeutic agents used to treat pancreatic cancer include 5-FU, leucovorin, oxaliplatin, irinotecan, gemcitabine, nab-paclitaxel (Abraxane ® ), FOLFIRINOX, FOLFOX, XELOX, and combinations thereof.
• therapeutic agents used to treat pancreatic cancer include 5-FU + leucovorin + oxaliplatin + irinotecan, 5-FU + nanoliposomal irinotecan, cisplatin + gemcitabine, leucovorin + nanoliposomal irinotecan, 5-FU + gemcitabine, and gemcitabine + nab-paclitaxel.
• Therapeutic treatments used to treat endometrial cancer include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy.
• the therapeutic treatments include Anti-angiogenesis therapy, Mammalian target of rapamycin (mTOR) inhibitors, Targeted therapy to treat a rare type of uterine cancer.
• mTOR Mammalian target of rapamycin
• Therapeutic agents used to treat endometrial cancer include carboplatin, paclitaxel, cisplatin, doxorubicin, ifosfamide, progesterone, anastrozole (Arimidex ® ), letrozole (Femara ® ), and exemestane (Aromasin ® ), pembrolizumab (Keytruda ® ), lenvatinib (Lenvima ® ), dostarlimab (Jemperli ® ), and combinations thereof.
• Therapeutic agents used to treat prostate cancer include enzalutamide (Xtandi ® ), leuprolide, trifluridine, tipiracil (Lonsurf), cabazitaxel, prednisone, abiraterone (Zytiga ® ), docetaxel, mitoxantrone, bicalutamide, LHRH, flutamide, ADT, sabizabulin (Veru-111), and combinations thereof.
• therapeutic agents used to treat prostate cancer include enzalutamide + leuprolide, trifluridine + tipiracil (Lonsurf), cabazitaxel + prednisone, abiraterone + prednisone, docetaxel + prednisone, mitoxantrone + prednisone, bicalutamide + LHRH, flutamide + LHRH, leuprolide + flutamide , and abiraterone + prednisone + ADT.
• the compound provided herein is administered with one or more therapeutic agents selected from a PI3K inhibitor, a Trop-2 binding agent, CD47 antagonist, a SIRP ⁇ antagonist, a FLT3R agonist, a PD-1 antagonist, a PD-L1 antagonist, an MCL1 inhibitor, a CCR8 binding agent, an HPK1 antagonist, a DGKa inhibitor, a CISH inhibitor, a PARP-7 inhibitor, a Cbl-b inhibitor, a KRAS inhibitor (e.g., a KRAS G12C or G12D inhibitor), a KRAS degrader, a beta-catenin degrader, a helios degrader, a CD73 inhibitor, an adenosine receptor antagonist, a TIGIT antagonist, a TREM1 binding agent, a TREM2 binding agent, a CD137 agonist, a GITR binding agent, an OX40 binding agent, and a C
• the compound provided herein is administered with one or more therapeutic agents selected from a PI3Kd inhibitor (e.g., idealisib), an anti-Trop-2 antibody drug conjugate (e.g., sacituzumab govitecan, datopotamab deruxtecan (DS-1062)), an anti-CD47 antibody or a CD47-blocking agent (e.g., magrolimab, DSP-107, AO-176, ALX-148, letaplimab (IBI-188), lemzoparlimab, TTI-621, TTI-622), an anti-SIRP ⁇ antibody (e.g., GS-0189), a FLT3L- Fc fusion protein (e.g., GS-3583), an anti-PD-1 antibody (pembrolizumab, nivolumab, zimberelimab), a small molecule PD-L1 inhibitor (e.g., GS-4224), an anti-PD
• the compound provided herein is administered with one or more therapeutic agents selected from idealisib, sacituzumab govitecan, magrolimab, GS-0189, GS- 3583, zimberelimab, GS-4224, GS-9716, GS-6451, quemliclustat (AB680), etrumadenant (AB928), domvanalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, axicabtagene ciloleucel and brexucabtagene autoleucel. IX.
• the present disclosure provides processes and intermediates useful for preparing the compounds disclosed herein or pharmaceutically acceptable salts thereof.
• Compounds disclosed herein can be purified by any of the means known in the art, including chromatographic means, including but not limited to high-performance liquid chromatography (HPLC), preparative thin layer chromatography, flash column chromatography, and ion exchange chromatography. Any suitable stationary phase can be used, including but not limited to, normal and reversed phases as well as ionic resins.
• the disclosed compounds are purified via silica gel and/or alumina chromatography.
• starting materials can be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product.
• the transformations shown in the schemes below can be performed in any order that is compatible with the functionality of the particular pendant groups.
• the methods of the present disclosure generally provide a specific enantiomer or diastereomer as the desired product, although the stereochemistry of the enantiomer or diastereomer was not determined in all cases.
• Intermediate 3-1 2-(3-(methoxymethoxy)-8-(trifluoromethoxy)naphthalen-1-yl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane [0406]
• Intermediate 3-1 was synthesized in a manner similar to Intermediate 5-6 using 1- bromo-3-(trifluoromethoxy)benzene instead of 4-bromo-2-chloro-1-fluorobenzene.
• LCMS 367.4 [M ⁇ CH3O] + .
• reaction mass was quenched with acetic acid (1.44 mL, 25.251 mmol) and extracted with ethyl acetate (2 x 90 mL).
• the combined organic layer was washed with brine (70 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to get the crude.
• the crude material was subjected to silica gel (100-200 mesh) column chromatography eluting with 8%- 10% ethyl acetate in petroleum ether to yield Intermediate 5-2.
• reaction mass was quenched with saturated aqueous sodium bicarbonate (20 mL) and added diethyl ether (75 mL) and ethyl acetate (25 mL) sequentially.
• the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give Intermediate 5-5.
• N-phenyl- bis(trifluoromethanesulfonimide) (2.26 g, 6.33 mmol) was added.
• diethyl ether 200 mL
• ethyl acetate 25 mL
• saturated aqueous sodium bicarbonate solution 25 mL
• the organic layer was washed sequentially with water (200 mL) and a mixture of water and saturated aqueous sodium bicarbonate solution (4:1 v:v, 200 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure give Intermediate 7-4.
• LCMS 439.0.
• Intermediate 8-1 2-(8-chloro-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5- tetramethyl-1,3,2-dioxaborolane [0419]
• Intermediate 8-1 was synthesized in a manner similar to Intermediate 5-6 using 6- bromo-2-chloro-3-fluorobenzoic acid instead of Intermediate 5-1.
• LCMS 367.3.
• Intermediate 11-1 4,4,5,5-tetramethyl-2-(6,7,8-trifluoro-3-(methoxymethoxy) naphthalen- 1-yl)-1,3,2-dioxaborolane [0420]
• Intermediate 11-1 was synthesized in a manner similar to Intermediate 7-5 using 6- bromo-2,3,4-trifluoro-benzoic acid instead of 6-bromo-3-fluoro-2-(trifluoromethoxy)benzoic acid.
• LCMS 369.1.
• N,N- diisopropylethylamine (11.1 mL, 63.5 mmol) was added over 2 min via syringe. After 11 min, the resulting mixture was warmed to room temperature. After 20 min, the resulting mixture was heated to 70°C. After 22 h, the resulting mixture was cooled to room temperature, and citric acid (3.0 g), diethyl ether (200 mL), and ethyl acetate (25 mL) were added sequentially. The organic layer was washed with water (200 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure.
• Intermediate 18-1 tert-butyl (1R,2S,5S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate
• Intermediate 18-1 was synthesized in a manner similar to Intermediate 17-7 using 8- (tert-butyl) 2-ethyl (1R,2S,5S)-4-oxo-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate instead of 8-(tert-butyl) 2-ethyl (1S,2S,5R)-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate.
• Intermediate 19-1 tert-butyl (1S,2R,5R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate
• Intermediate 19-1 was synthesized in a manner similar to Intermediate 18-1 using 8- (tert-butyl) 2-ethyl (1S,2R,5R)-4-oxo-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate instead of 8-(tert-butyl) 2-ethyl (1R,2S,5S)-4-oxo-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate.
• Intermediate 20-5 4-(2,4,5-trichloro-8-fluoropyrido[4,3-d]pyrimidin-7-yl)naphthalen-2-yl pivalate [0461]
• Intermediate 20-5 was synthesized in a manner similar to Intermediate 17-5 using Intermediate 20-4a and Intermediate 20-4b instead of Intermediate 17-4.
• Intermediate 21-1 tert-butyl (1R,2R,5S)-2-(((tert-butyldimethylsilyl)oxy)methyl)-3,8- diazabicyclo[3.2.1]octane-8-carboxylate
• Intermediate 21-1 was synthesized in a manner similar to Intermediate 17-7 using 8- (tert-butyl) 2-ethyl (1R,2R,5S)-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate instead of 8- (tert-butyl) 2-ethyl (1S,2S,5R)-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate.
• reaction mixture was partitioned between EtOAc and water, the organic phase was washed with brine, dried MgSO 4 , filtered and concentrated. The residue was dissolved in a mixture of acetonitrile/acetone 1:1 (2 ml) then DIPEA (0.05 ml, 0.28 mmol), morpholine (0.029 ml, 0.34 mmol), and NaI (42 mg, 0.284 mmol) were added. Reaction mixture was stirred at 80°C for 2 h. Ethyl acetate, and saturated aqueous sodium bicarbonate solution were added sequentially. The organic layer was washed with water, was dried over anhydrous magnesium sulfate, was filtered, and was concentrated under reduced pressure to give Intermediate 29-2.
• Methanesulfonyl chloride (8.9 ⁇ L, 115 ⁇ mol) was added followed by triethylamine (16 ⁇ L, 115 ⁇ mol). The mixture was stirred at 0°C for 30 min. Brine (1 mL) and saturated aqueous sodium carbonate (1 mL) were added and the mixture was extracted with ethyl acetate (2 x 1 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo.
• Potassium bis(trimethylsilyl)amide solution (1.0 M in tetrahydrofuran, 318 ⁇ L, 320 ⁇ mol) was added over 1 min via syringe, and the resulting mixture was heated to 90°C. After 120 min, the resulting mixture was cooled to room temperature, and saturated aqueous sodium bicarbonate solution (5 mL), diethyl ether (40 mL), and ethyl acetate (20 mL) were added sequentially. The organic layer was washed with water (20 mL), was dried over anhydrous magnesium sulfate, was filtered, and was concentrate under reduced pressure.
• Intermediate 53-8 tert-butyl (5S,5aS,6S,9R)-12-(ethylthio)-1-fluoro-2-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5-methyl-5a,6,7,8,9,10- hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalene-14- carboxylate [0516]
• Intermediate 53-8 was synthesized in a manner similar to Intermediate 13-8 using Intermediate 53-7 instead of Intermediate 13-7.
• Intermediate 54-3 2-(7-fluoro-3-(methoxymethoxy)-8-((trifluoromethyl)thio) naphthalen- 1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [0522]
• Intermediate 54-3 was synthesized in a manner similar to Intermediate 7-5 using Intermediate 54-2 instead of Intermediate 7-3.
• Intermediate 62-1 methyl 2-allyl-4,5-difluorobenzoate [0527] Intermediate 62-1 was synthesized in a manner similar to intermediate 7-2 using methyl 2-bromo-4,5-difluorobenzoate instead of intermediate 7-1 and using allyl bromide instead of 3- chloro-2-(methoxymethoxy)prop-1-ene.
• Triethylamine (1.0 mL) was added via syringe, and the resulting mixture was concentrated under reduced pressure. Saturated aqueous sodium carbonate (10 mL) and water were added sequentially. The aqueous layer was extracted with dichloromethane (4 ⁇ 35 mL). The combined organic layers were dried over anhydrous magnesium sulfate, were filtered, and were concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (0 to 100% methanol in dichloromethane) to give intermediate 63-4. LCMS: 390.1.
• the resulting solution was stirred at 50 ⁇ C for 1 hour before it was cooled to room temperature.
• the solution was transferred to a reaction vial containing Pd(dppf)Cl 2 (3.70 mg, 0.0052 mmol), potassium phosphate (36.6 mg, 0.16 mmol) and degassed water (0.1 mL) at rt under nitrogen atmosphere.
• the reaction mixture was stirred at 90°C for 10 minutes before it was cooled to room temperature.
• the mixture was washed with water (2 mL) and extracted with ethyl acetate (3 x 5 mL). The organic layer was collected and combined, dried over magnesium sulfate, concentrated under reduced pressure.
• Intermediate 77-1 3-benzyl 8-(tert-butyl) (1S,2R,5R)-2-formyl-3,8-diazabicyclo [3.2.1]octane-3,8-dicarboxylate [0563]
• Intermediate 77-1 was synthesized in a manner similar to intermediate 27-3 using 8-(tert- butyl) 2-ethyl (1S,2R,5R)-4-oxo-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate instead of 8- (tert-butyl) 2-ethyl (1S,2S,5R)-3,8-diazabicyclo[3.2.1]octane-2,8-dicarboxylate.
• Intermediate 77-3 tert-butyl (1S,2S,5R)-2-(2-methoxyvinyl)-3,8-diazabicyclo[3.2.1]octane- 8-carboxylate [0565] Intermediate 77-3 was synthesized in a manner similar to intermediate 27-5 using intermediate 77-2 instead of intermediate 27-4.
• Intermediate 80-7 tert-butyl (5S,5aS,6S,9R)-5-ethyl-12-(ethylthio)-1-fluoro-2-(7-fluoro-3- (methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-5a,6,7,8,9,10-hexahydro- 5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalene-14-carboxylate [0583] Intermediate 80-7 was synthesized in a manner similar to Intermediate 13-8 using Intermediate 80-6 instead of Intermediate 13-7.
• Intermediate 113-1 tert-butyl (5aR,6S,9R)-12-(ethylsulfonyl)-2-(8-ethynyl-7- fluoronaphthalen-1-yl)-1-fluoro-4,5,5a,6,7,8,9,10-octahydro-3,10a,11,13,14-pentaaza-6,9- methanonaphtho[1,8-ab]heptalene-14-carboxylate [0686] Intermediate 113-1 was prepared in a manner analogous to Intermediate 122-2 using (8- ethynyl-7-fluoronaphthalen-1-yl) pinacol boronate.
• Intermediate 120-1 tert-butyl (5aR,6S,9R)-12-(ethylsulfonyl)-1-fluoro-2-(7-fluoro-3- (methoxymethoxy)-8-(trifluoromethoxy)naphthalen-1-yl)-4,5,5a,6,7,8,9,10-octahydro- 3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]heptalene-14-carboxylate [0708] Intermediate 120-1 was synthesized in a manner similar to intermediate 102-1 using intermediate 65-1 instead of intermediate 7-5. LCMS: 706.2.
• reaction mixture was quenched with saturated aqueous NH 4 Cl solution, and the aqueous phase was extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated. The crude mixture was purified by column chromatography (silica gel, 0 ⁇ 20% EtOAc in hexanes) to afford the title compound.
• Intermediate 132-6 tert-butyl (6aS,7S,10R)-2-chloro-1-fluoro-13-(((2R,7aS)-2- fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)-5,6,6a,7,8,9,10,11-octahydro-4H- 3,11a,12,14,15-pentaaza-7,10-methanocyclohepta[4,5]cycloocta[1,2,3-de]naphthalene-15- carboxylate [0730] Intermediate 132-6 was synthesized in a manner similar to Intermediate 53-10 using Intermediate 132-5 instead of Intermediate 53-9. LCMS: 591.3.
• Intermediate 132-7 tert-butyl (6aS,7S,10R)-1-fluoro-2-(7-fluoro-3-(methoxymethoxy)-8- ((triisopropylsilyl)ethynyl)naphthalen-1-yl)-13-(((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy)-5,6,6a,7,8,9,10,11-octahydro-4H-3,11a,12,14,15-pentaaza- 7,10-methanocyclohepta[4,5]cycloocta[1,2,3-de]naphthalene-15-carboxylate [0731] Intermediate 132-7 was synthesized in a manner similar to Intermediate 2-1 using Intermediate 132-6 instead of Intermediate 17-9.
• reaction mixture was stirred at 0°C for 5 mins, then NaBH 4 (64.57 mg, 1.71 mmol, 8 eq) was added, the reaction mixture was stirred at 60°C for 1 hr under N 2 .
• To the reaction mixture was added sat.aq. NH 4 Cl (10 mL) slowly and the reaction mixture was stirred at 0°C for 0.5 hr under N 2 , and then extracted with EtOAc (10 mL * 3). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
• Intermediate 150-1 ((3S,7aS)-3-(((1,1,1,3,3,3-hexafluoropropan-2- yl)oxy)methyl)tetrahydro-1H-pyrrolizin-7a(5H)-yl)methyl benzoate [0765]
• Intermediate 150-1 was synthesized in a manner similar to intermediate 109-1 using intermediate 119-2 instead of intermediate 63-2 and using 1,1,1,3,3,3-hexafluoropropan-2-ol instead of 1,1,1,3,3,3-hexafluoro-2-methyl-propan-2-ol.
• Intermediate 156-1 8-(tert-butyl) 3-(2-(trimethylsilyl)ethyl) (1S,2S,5R)-2-(prop-1-en-2-yl)- 3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate [0768]
• Intermediate 156-1 was synthesized in a manner similar to 64-1 using intermediate 86-4 instead of intermediate 61-1.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (12)

Applications Claiming Priority (6)

Publications (1)

Family

ID=86383159

Family Applications (1)

Country Status (16)

Cited By (31)

Families Citing this family (8)

Citations (322)